WEST Search History

DATE: Wednesday, November 13, 2002

Set Name		Hit Count Set Name result set		
DB=U	SPT,PGPB,EPAB,DWPI,TDBD; THES=ASSIGNEE; PLUR=YES;			
OP=ADJ				
L19	recombinant same relaxin and stroke?	0	L19	
L18	recombinant adj relaxin and (ischemic same cardiac)	1	L18	
L17	recombinant adj relaxin and (ischemic same wound)	1	L17	
L16	recombinant adj relaxin and (pulmonary same hypertension)	1	L16	
L15	recombinant adj relaxin and hypertension and (renal same function?)	0	L15	
L14	recombinant adj relaxin and (vasodilation or vasodilator?)and hypertension	1	L14	
L13	relaxin and stroke?	9	L13	
L12	relaxin and (ischemic same cardiac)	10	L12	
L11	relaxin and (ischemic same wound)	11	L11	
L10	relaxin and (renal same hypertension)	13	L10	
L9	relaxin and (pulmonary same hypertension)	8	L9	
L8	relaxin and hypertension and (renal same function?)	3	L8	
L7	relaxin and (vasodilation or vasodilator?) and hypertension and (renal same function?)	2	L7	
L6	relaxin and (vasodilation or vasodilator?) and hypertension	17	L6	
L5	relaxin and (vasodilation or vasodilator?)	47	L5	
L4	5166191.pn.	2	L4	
L3	08050745.ap.	0	L3	
L2	unemori-elaine.in.	7	L2	
L1	unemori-elaine-n\$.in.	1	L1	

END OF SEARCH HISTORY

Generate Collection

Print

Search Results - Record(s) 1 through 9 of 9 returned.

☐ 1. Document ID: US 20020151681 A1

L13: Entry 1 of 9

File: PGPB

Oct 17, 2002

PGPUB-DOCUMENT-NUMBER: 20020151681

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020151681 A1

TITLE: Nucleic acids, proteins and antibodies

PUBLICATION-DATE: October 17, 2002

INVENTOR - INFORMATION:

NAME

CITY

STATE

COUNTRY

RULE-47

Rosen, Craig A.

Laytonsville

MD

US

....

Ruben, Steven M.

Olney

MD

US

US-CL-CURRENT: 530/350; 435/320.1, 435/325, 435/69.3, 536/23.5

Full Title Citation Front Review Classification Date Reference Sequences Attachments

KMC Draw Desc Image

☐ 2. Document ID: US 20020114848 A1

L13: Entry 2 of 9

File: PGPB

Aug 22, 2002

PGPUB-DOCUMENT-NUMBER: 20020114848

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020114848 A1

TITLE: Methods for regulating levels of zinc, cadmium and calcium in humans and for diagnosing, or screening for the risk of developing, diseases associated with abnormal levels of cadmium, zinc and calcium in body fluids and tissues

PUBLICATION-DATE: August 22, 2002

INVENTOR-INFORMATION:

NAME

CITY

STATE

COUNTRY

RULE-47

Woods, Gordon L.

Moscow

ID

US

US-CL-CURRENT: 424/654; 514/171, 514/43

Full Title Citation Front Review Classification Date Reference Sequences Attachments

KWIC Draw Desc Image

☐ 3. Document ID: US 20020039599 A1

L13: Entry 3 of 9

File: PGPB

Apr 4, 2002

PGPUB-DOCUMENT-NUMBER: 20020039599

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020039599 A1

TITLE: Methods of diagnosing and treating small intestinal bacterial overgrowth

(SIBO) and SIBO-related conditions

PUBLICATION-DATE: April 4, 2002

INVENTOR-INFORMATION:

NAME

CITY

STATE

COUNTRY

RULE-47

Lin, Henry C.

Manhattan Beach

CA

Pimentel, Mark

Los Angeles

Full Title Citation Front Review Classification Date Reference Sequences Attachments

CA

US US

US-CL-CURRENT: 424/558; 514/2, 514/714

KWIC Draw Desc Image

4. Document ID: US 5888764 A

L13: Entry 4 of 9

File: USPT

Mar 30, 1999

US-PAT-NO: 5888764

DOCUMENT-IDENTIFIER: US 5888764 A

TITLE: Human fas gene promoter region

DATE-ISSUED: March 30, 1999

INVENTOR-INFORMATION:

NAME CITY

7 - STATE ZIP CODE

COUNTRY

Mountz; John D. Liu; Changdan Birmingham Alabaster

Full Title Citation Front Review Classification Date Reference Sequences Attachments

AL AL

Cheng; Jianhua Koopman; William J.

Alabaster Indian Springs

AL AL

Zhou; Tong

W. Stonebrook Pl.

 \mathtt{AL}

KWIC Draw Desc Image

☐ 5. Document ID: US 5811388 A

L13: Entry 5 of 9

File: USPT

Sep 22, 1998

US-PAT-NO: 5811388

DOCUMENT-IDENTIFIER: US 5811388 A

TITLE: Delivery of drugs to the lower GI tract

DATE-ISSUED: September 22, 1998

INVENTOR-INFORMATION:

NAME

CITY

STATE

ZIP CODE COUNTRY

Friend; David R.

Menlo Park

CA

Wong; David

San Francisco

CA

US-CL-CURRENT: $\underline{514/2}$; $\underline{424/465}$, $\underline{424/474}$, $\underline{424/475}$, $\underline{424/479}$, $\underline{424/481}$, $\underline{424/485}$, $\underline{424/485}$, $\underline{424/485}$, $\underline{424/485}$, $\underline{514/179}$, $\underline{514/180}$, $\underline{514/181}$, $\underline{514/182}$, $\underline{514/21}$, $\underline{514/777}$, $\underline{514/780}$, $\underline{514/782}$, $\underline{514/960}$, $\underline{514/961}$

Full Title Citation Front Review Classification Date Reference Sequences Attachments

RMC Draw Desc Image

☐ 6. Document ID: US 5378603 A

L13: Entry 6 of 9

File: USPT

Jan 3, 1995

US-PAT-NO: 5378603

DOCUMENT-IDENTIFIER: US 5378603 A

TITLE: Method and composition for identifying substances which activate

transcription of the LDL receptor gene

DATE-ISSUED: January 3, 1995

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY Brown; Michael S. Dallas Goldstein; Joseph L. Dallas TX Russell; David W. Dallas Sudhof; Thomas C. Dallas TX Martin, Jr.; David W. San Francisco

US-CL-CURRENT: 435/6; 435/29, 435/4, 436/817

Full Title Citation Front Review Classification Date Reference Sequences Attachments

KWMC Draw Desc Image

7. Document ID: US 5256545 A

L13: Entry 7 of 9

File: USPT

Oct 26, 1993

US-PAT-NO: 5256545

DOCUMENT-IDENTIFIER: US 5256545 A

TITLE: Sterol Regulatory Elements

DATE-ISSUED: October 26, 1993

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY Brown; Michael S. Dallas TX

Brown; Michael S. Dallas TX
Goldstein; Joseph L. Dallas TX
Russell; David W. Dallas TX
Sudhof; Thomas C. Dallas TX

US-CL-CURRENT: $\underline{435}/\underline{69.1}$; $\underline{435}/\underline{252.3}$, $\underline{435}/\underline{320.1}$, $\underline{435}/\underline{358}$, $\underline{435}/\underline{464}$, $\underline{435}/\underline{465}$, $\underline{536}/\underline{24.1}$

Full Title Citation Front Review Classification Date Reference Sequences Attachments KNNC (

KWC Draw Desc Image

☐ 8. Document ID: US 5215910 A

L13: Entry 8 of 9

File: USPT

Jun 1, 1993

US-PAT-NO: 5215910

DOCUMENT-IDENTIFIER: US 5215910 A

TITLE: Host cells transformed with sterol regulatory elements

DATE-ISSUED: June 1, 1993

INVENTOR-INFORMATION:

CITY ZIP CODE NAME STATE COUNTRY Brown; Michael S. Dallas TXGoldstein; Joseph L. Dallas TXRussell; David W. Dallas TX Sudhof; Thomas C. Dallas ΤX

US-CL-CURRENT: 435/350; 435/320.1, 435/358, 435/363, 435/367, 435/370, 435/69.1, 536/24.1

Full Title Citation Front Review Classification Date Reference Sequences Attachments

KMC Draw Desc Image

9. Document ID: US 4935363 A

L13: Entry 9 of 9

File: USPT

Jun 19, 1990

US-PAT-NO: 4935363

DOCUMENT-IDENTIFIER: US 4935363 A

TITLE: Sterol regulatory elements

DATE-ISSUED: June 19, 1990

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY Brown; Michael S. Dallas TX Goldstein; Joseph L. Dallas TXRussell; David W. Dallas TXSudhof; Thomas C. Dallas TX

US-CL-CURRENT: $\frac{435}{69.1}$; $\frac{435}{207}$, $\frac{435}{212}$, $\frac{435}{226}$, $\frac{435}{375}$, $\frac{435}{41}$, $\frac{435}{45}$, $\frac{435}{69.5}$, $\frac{435}{69.51}$, $\frac{435}{69.52}$, $\frac{536}{23.2}$, $\frac{536}{23.5}$, $\frac{536}{23.5}$, $\frac{536}{23.51}$, $\frac{536}{23.52}$

Full Title Citation Front Review Classification Date Reference Sequences Attachments

KMIC Draw, Desc Image

Generate Collection

Print

Term	Documents
RELAXIN.DWPI,TDBD,EPAB,USPT,PGPB.	655
RELAXINS.DWPI,TDBD,EPAB,USPT,PGPB.	49
STROKE?	0
STROKEA.DWPI,TDBD,EPAB,USPT,PGPB.	2
STROKEB.DWPI,TDBD,EPAB,USPT,PGPB.	1
STROKED.DWPI,TDBD,EPAB,USPT,PGPB.	2774
STROKEE.DWPI,TDBD,EPAB,USPT,PGPB.	10
STROKEL.DWPI,TDBD,EPAB,USPT,PGPB.	1
STROKEN.DWPI,TDBD,EPAB,USPT,PGPB.	10
STROKER.DWPI,TDBD,EPAB,USPT,PGPB.	187
STROKES.DWPI,TDBD,EPAB,USPT,PGPB.	39254
(RELAXIN AND STROKE?).USPT,PGPB,EPAB,DWPI,TDBD.	9

There are more results than shown above. Click here to view the entire set.

Display Format:	-	Change Format

Previous Page

Next Page

Generate Collection

Print

Search Results - Record(s) 1 through 10 of 10 returned.

☐ 1. Document ID: US 20020122814 A1

L12: Entry 1 of 10

File: PGPB

Sep 5, 2002

PGPUB-DOCUMENT-NUMBER: 20020122814

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020122814 A1

TITLE: Uses for medical devices having a lubricious, nitric oxide-releasing coating

PUBLICATION-DATE: September 5, 2002

INVENTOR-INFORMATION:

NAME

CITY

STATE

COUNTRY

RULE-47

Tedeschi, Eugene

Santa Rosa

CA

US

ОБЕ-4.

Shah, Chirag B.

North Attleboro

MA

US

US-CL-CURRENT: <u>424</u>/<u>426</u>; <u>424</u>/<u>718</u>, <u>427</u>/<u>2.24</u>

Full Title Citation Front Review Classification Date Reference Sequences Attachments

KMC Draw Desc Image

☐ 2. Document ID: US 20020022046 A1

L12: Entry 2 of 10

File: PGPB

Feb 21, 2002

PGPUB-DOCUMENT-NUMBER: 20020022046

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020022046 A1

TITLE: USES FOR MEDICAL DEVICES HAVING A LUBRICIOUS, NITRIC OXIDE-RELEASING COATING

PUBLICATION-DATE: February 21, 2002

INVENTOR-INFORMATION:

NAME

CITY

STATE

COUNTRY

RULE-47

Tedeschi, Eugene

Santa Rosa

CA

US

Shah, Chirag B.

North Attleboro

MA

US

US-CL-CURRENT: 424/423

Full Title Citation Front Review Classification Date Reference Sequences Attachments

KWMC | Draw Desc | Image

☐ 3. Document ID: US 20020019349 A1

L12: Entry 3 of 10

File: PGPB

Feb 14, 2002

PGPUB-DOCUMENT-NUMBER: 20020019349

PGPUB-FILING-TYPE: new

Record List Display

DOCUMENT-IDENTIFIER: US 20020019349 A1

TITLE: Use of relaxin treat diseases related to vasoconstriction

PUBLICATION-DATE: February 14, 2002

INVENTOR-INFORMATION:

CITY NAME STATE COUNTRY RULE-47 Conrad, Kirk P. Cranberry Township PA US Lewis, Martyn Menlo park CA US Unemori, Elaine N. Oakland CA US Huang, Xinfan Menlo Park CA US Tozzi, Carol A. Jackson ŊJ US

US-CL-CURRENT: 514/12

Full Title Citation Front Review Classification Date Reference Sequences Attachments KVMC Draw Desc Image

☐ 4. Document ID: US 6479654 B1

L12: Entry 4 of 10

File: USPT

Nov 12, 2002

US-PAT-NO: 6479654

DOCUMENT-IDENTIFIER: US 6479654 B1

TITLE: Forms of the angiogenic factor vascular endothelial cell growth factor: VEGF

DATE-ISSUED: November 12, 2002

INVENTOR-INFORMATION:

NAME

CITY

STATE ZIP CODE COUNTRY

Baird; Andrew

San Diego

CA

Andreason; Grai

La Jolla

CA

US-CL-CURRENT: <u>536/23.5</u>; <u>435/320.1</u>, <u>536/23.1</u>

Full Title Citation Front Review Classification Date Reference Sequences Attachments

KWC Draw, Desc Image

☐ 5. Document ID: US 6440726 B1

L12: Entry 5 of 10

File: USPT

Aug 27, 2002

US-PAT-NO: 6440726

DOCUMENT-IDENTIFIER: US 6440726 B1

TITLE: Expression vectors comprising multiple shear stress responsive elements (SSRE) and methods of use for treating disorders related to vasculogenesis and/or angiogenesis in a shear stress environment

DATE-ISSUED: August 27, 2002

INVENTOR-INFORMATION:

NAME

CITY STATE ZIP CODE

COUNTRY

Resnick; Nitzan

Haifa

IL

US-CL-CURRENT: 435/320.1; 435/325, 435/455, 435/69.1, 514/44

KWAC Draw Desc Image | Full Title Citation Front Review Classification Date Reference Sequences Attachments ☐ 6. Document ID: US 6379691 B1 L12: Entry 6 of 10 File: USPT Apr 30, 2002 US-PAT-NO: 6379691 DOCUMENT-IDENTIFIER: US 6379691 B1 TITLE: Uses for medical devices having a lubricious, nitric oxide-releasing coating DATE-ISSUED: April 30, 2002 INVENTOR-INFORMATION: ZIP CODE COUNTRY STATE NAME CITY Tedeschi; Eugene Santa Rosa CA Shah; Chirag B. Attleboro MA US-CL-CURRENT: 424/423; 424/422, 424/78.08, 514/824 Full Title Citation Front Review Classification Date Reference Sequences Attachments KMIC Draw Desc Image 7. Document ID: US 6171586 B1 L12: Entry 7 of 10 File: USPT Jan 9, 2001 US-PAT-NO: 6171586 DOCUMENT-IDENTIFIER: US 6171586 B1 TITLE: Antibody formulation DATE-ISSUED: January 9, 2001 INVENTOR-INFORMATION: STATE ZIP CODE NAME CITY COUNTRY Lam; Xanthe M. San Francisco CA Oeswein; James Q. Moss Beach CA

Ongpipattanakul; Boonsri Bangkok THShahrokh; Zahra San Francisco CA

San Mateo Wang; Sharon X. CA Weissburg; Robert P. Greenville DE Wong; Rita L. San Mateo CA

US-CL-CURRENT: 424/130.1; 424/141.1, 424/152.1, 424/154.1, 424/173.1, 530/388.75

Full Title Citation Front Review Classification Date Reference Sequences Attachments KMC Draw Desc Image

☐ 8. Document ID: US 6013780 A

L12: Entry 8 of 10

File: USPT

Jan 11, 2000

US-PAT-NO: 6013780

DOCUMENT-IDENTIFIER: US 6013780 A

TITLE: VEGF.sub.145 expression vectors

DATE-ISSUED: January 11, 2000

INVENTOR - INFORMATION:

CITY STATE ZIP CODE NAME COUNTRY Neufeld; Gera Haifa IL Keshet; Eli Kiryat Yam IL Vlodavsky; Israel Mevaseret Zion ILPoltorak; Zoya Jerusalem IL

US-CL-CURRENT: 536/23.1; 435/320.1

	Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
--	------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------

KMIC Draw Desc Image

9. Document ID: US 5972894 A

L12: Entry 9 of 10

File: USPT

Oct 26, 1999

US-PAT-NO: 5972894

DOCUMENT-IDENTIFIER: US 5972894 A

TITLE: Peptides having potassium channel opener activity

DATE-ISSUED: October 26, 1999

INVENTOR - INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Sinackevich; Nickolai V. St. Petersburg RU
Rakhilov; Alexi M. St. Petersburg RU
Maslennikov; Sergei V. St. Petersburg RU

Green; Lawrence R. Tacoma WA

US-CL-CURRENT: 514/16; 514/19

Full Title Citation Front Review Classification Date Reference Sequences Attachments

KMC Draw Desc Image

10. Document ID: US 2002019349 A1 WO 200158468 A1 AU 200136886 A

L12: Entry 10 of 10

File: DWPI

Feb 14, 2002

DERWENT-ACC-NO: 2001-514619

DERWENT-WEEK: 200214

COPYRIGHT 2002 DERWENT INFORMATION LTD

TITLE: Treating pulmonary or renal hypertension and an ischemic condition,

increasing vasodilation and renal function, promoting wound healing and increasing

production of angiogenic cytokine, comprises administering relaxin

INVENTOR: CONRAD, K P; HUANG, X ; LEWIS, M ; TOZZI, C A ; UNEMORI, E N

PRIORITY-DATA: 2000US-242216P (October 20, 2000), 2000US-181408P (February 9, 2000),

2000US-200284P (April 28, 2000), 2001US-0780752 (February 9, 2001)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
US 2002019349 A1	February 14, 2002		000	A61K038/00
WO 200158468 A1	August 16, 2001	E	073	A61K038/00
AU 200136886 A	August 20, 2001		000	A61K038/00

INT-CL (IPC): $\underline{A61}$ \underline{K} $\underline{38/00}$

Full Title Citation Front Review Classification Date Reference Sequences Attachments KMC Draw Desc Image

Generate Collection Print

Term	Documents
RELAXIN.DWPI,TDBD,EPAB,USPT,PGPB.	655
RELAXINS.DWPI,TDBD,EPAB,USPT,PGPB.	49
ISCHEMIC.DWPI,TDBD,EPAB,USPT,PGPB.	14176
ISCHEMICS.DWPI,TDBD,EPAB,USPT,PGPB.	20
CARDIAC.DWPI,TDBD,EPAB,USPT,PGPB.	54732
CARDIACS.DWPI,TDBD,EPAB,USPT,PGPB.	79
(RELAXIN AND (ISCHEMIC SAME CARDIAC)).USPT,PGPB,EPAB,DWPI,TDBD.	10
(RELAXIN AND (ISCHEMIC SAME CARDIAC)).USPT,PGPB,EPAB,DWPI,TDBD.	. 10

Display Format: - Change Format

Previous Page Next Page

Generate Collection

Print

Search Results - Record(s) 1 through 11 of 11 returned.

1. Document ID: US 20020151681 A1

L11: Entry 1 of 11

File: PGPB

Oct 17, 2002

PGPUB-DOCUMENT-NUMBER: 20020151681

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020151681 A1

TITLE: Nucleic acids, proteins and antibodies

PUBLICATION-DATE: October 17, 2002

INVENTOR-INFORMATION:

NAME CITY STATE COUNTRY RULE-47

Rosen, Craig A. Laytonsville MD US Ruben, Steven M. Olney MD US

US-CL-CURRENT: 530/350; 435/320.1, 435/325, 435/69.3, 536/23.5

Full Title Citation Front Review Classification Date Reference Sequences Attachments KMC Draw Desc Image

☐ 2. Document ID: US 20020019349 A1

File: PGPB

Feb 14, 2002

PGPUB-DOCUMENT-NUMBER: 20020019349

PGPUB-FILING-TYPE: new

L11: Entry 2 of 11

DOCUMENT-IDENTIFIER: US 20020019349 A1

TITLE: Use of relaxin treat diseases related to vasoconstriction

PUBLICATION-DATE: February 14, 2002

INVENTOR-INFORMATION:

NAME CITY STATE COUNTRY RULE-47 Conrad, Kirk P. Cranberry Township PA US Lewis, Martyn Menlo park CA US Unemori, Elaine N. Oakland US CA Huang, Xinfan Menlo Park CA US Tozzi, Carol A. Jackson NJ US

US-CL-CURRENT: 514/12

Full Title Citation Front Review Classification Date Reference Sequences Attachments KMC Draw Desc Image

☐ 3. Document ID: US 20010018418 A1

Record List Display

L11: Entry 3 of 11

File: PGPB

Aug 30, 2001

PGPUB-DOCUMENT-NUMBER: 20010018418

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20010018418 A1

TITLE: Method of promoting angiogenesis

PUBLICATION-DATE: August 30, 2001

INVENTOR-INFORMATION:

NAME

CITY

STATE COUNTRY

RULE-47

Unemori, Elaine

Oakland

CA

US

US-CL-CURRENT: 514/12; 424/43

Full Title Citation Front Review Classification Date Reference Sequences Attachments

KMMC Draw Desc Image

☐ 4. Document ID: US 6479654 B1

L11: Entry 4 of 11

File: USPT

Nov 12, 2002

US-PAT-NO: 6479654

DOCUMENT-IDENTIFIER: US 6479654 B1

TITLE: Forms of the angiogenic factor vascular endothelial cell growth factor: VEGF

DATE-ISSUED: November 12, 2002

INVENTOR-INFORMATION:

NAME

CITY

STATE

ZIP CODE

COUNTRY

Baird; Andrew

San Diego

CA

Andreason; Grai

La Jolla

Full Title Citation Front Review Classification Date Reference Sequences Attachments

CA

US-CL-CURRENT: <u>536/23.5</u>; <u>435/320.1</u>, <u>536/23.1</u>

KWIC Draw Desc Image

☐ 5. Document ID: US 6440726 B1

L11: Entry 5 of 11

File: USPT

Aug 27, 2002

US-PAT-NO: 6440726

DOCUMENT-IDENTIFIER: US 6440726 B1

TITLE: Expression vectors comprising multiple shear stress responsive elements (SSRE) and methods of use for treating disorders related to vasculogenesis and/or angiogenesis in a shear stress environment

DATE-ISSUED: August 27, 2002

INVENTOR-INFORMATION:

NAME

CITY STAT

STATE ZIP CODE

COUNTRY

Resnick; Nitzan

Haifa

IL

US-CL-CURRENT: 435/320.1; 435/325, 435/455, 435/69.1, 514/44

Full Title Citation Front Review Classification Date Reference Sequences Attachments

KMIC Draw Desc Image

☐ 6. Document ID: US 6413770 B1

L11: Entry 6 of 11

File: USPT

Jul 2, 2002

US-PAT-NO: 6413770

DOCUMENT-IDENTIFIER: US 6413770 B1

TITLE: NL4 tie ligand homologue nucleic acid

DATE-ISSUED: July 2, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Godowski; Paul	Burlingame	CA		
Gurney; Austin	Belmont	CA		
Hillan; Kenneth J.	San Francisco	CA		
Botstein; David	Belmont	CA		
Goddard; Audrey	San Francisco	CA		
Roy; Margaret	San Francisco	CA		
Ferrara; Napoleone	San Francisco	CA		
Tumas; Daniel	Orinda	CA		
Schwall; Ralph	Pacifica	CA		

US-CL-CURRENT: $\frac{435}{325}$; $\frac{435}{252.3}$, $\frac{435}{254.11}$, $\frac{435}{320.1}$, $\frac{435}{69.1}$, $\frac{530}{350}$, $\frac{536}{23.1}$, $\frac{536}{23.5}$

Full Title Citation Front Review Classification Date Reference Sequences Attachments

KMC Draw Desc Image

7. Document ID: US 6348351 B1

L11: Entry 7 of 11

File: USPT

Feb 19, 2002

US-PAT-NO: 6348351

DOCUMENT-IDENTIFIER: US 6348351 B1

TITLE: Tie receptor tyrosine kinase ligand homologues

DATE-ISSUED: February 19, 2002

INVENTOR-INFORMATION:

INVENTOR INFORMATION.				
NAME	CITY	STATE	ZIP CODE	COUNTRY
Fong; Sherman	Alameda	CA		
Ferrara; Napoleone	San Francisco	CA		
Goddard; Audrey	San Francisco	CA		
Godowski; Paul J.	Burlingame	CA		
Gurney; Austin L.	Belmont	CA		
Hillan; Kenneth	San Francisco	CA		
Williams; P. Mickey	Half Moon Bay	CA		

US-CL-CURRENT: $\frac{435}{325}$; $\frac{435}{252.3}$, $\frac{435}{254.11}$, $\frac{435}{320.1}$, $\frac{435}{69.1}$, $\frac{530}{350}$, $\frac{536}{23.1}$, $\frac{536}{23.5}$

Full Title Citation Front Review Classification Date Reference Sequences Attachments

KAiC Draw Desc Image

☐ 8. Document ID: US 6211147 B1

L11: Entry 8 of 11

File: USPT

Apr 3, 2001

US-PAT-NO: 6211147

DOCUMENT-IDENTIFIER: US 6211147 B1

TITLE: Method of promoting angiogenesis using relaxin

DATE-ISSUED: April 3, 2001

INVENTOR-INFORMATION:

NAME

CITY

STATE

ZIP CODE COUNTRY

Unemori; Elaine

Oakland

CA

US-CL-CURRENT: 514/12; 435/69.1, 530/399

Full Title Citation Front Review Classification Date Reference Sequences Attachments

KMMC | Draw Desc | Image

☐ 9. Document ID: US 6074873 A

L11: Entry 9 of 11

File: USPT

Jun 13, 2000

US-PAT-NO: 6074873

DOCUMENT-IDENTIFIER: US 6074873 A

TITLE: Nucleic acids encoding NL-3

DATE-ISSUED: June 13, 2000

INVENTOR-INFORMATION:

ZIP CODE NAME CITY STATE COUNTRY

Alameda CA Fong; Sherman Ferrara; Napoleone San Francisco CA Goddard; Audrey San Francisco CA Godowski; Paul J. Burlingame CA Gurney; Austin L. Belmont CASan Francisco CA Hillan; Kenneth Williams; P. Mickey Half Moon Bay CA

US-CL-CURRENT: 435/325; 435/252.3, 435/254.11, 435/320.1, 435/69.1, 530/350, 536/23.1, 536/23.5

Full Title Citation Front Review Classification Date Reference Sequences Attachments

KMC Draw, Desc Image

☐ 10. Document ID: WO 9706814 A1

L11: Entry 10 of 11

File: EPAB

Feb 27, 1997

PUB-NO: WO009706814A1

DOCUMENT-IDENTIFIER: WO 9706814 A1 TITLE: METHOD OF PROMOTING ANGIOGENESIS PUBN-DATE: February 27, 1997

INVENTOR - INFORMATION:

NAME

COUNTRY

UNEMORI, ELAINE

INT-CL (IPC): $A61 \times 38/00$ EUR-CL (EPC): $A61 \times 038/22$

Full Title Citation Front Review Classification Date Reference Sequences Attachments

RMC Draw Desc Image

☐ 11. Document ID: US 2002019349 A1 WO 200158468 A1 AU 200136886 A

L11: Entry 11 of 11

File: DWPI

Feb 14, 2002

DERWENT-ACC-NO: 2001-514619

DERWENT-WEEK: 200214

COPYRIGHT 2002 DERWENT INFORMATION LTD

TITLE: Treating pulmonary or renal hypertension and an ischemic condition,

increasing vasodilation and renal function, promoting wound healing and increasing

production of angiogenic cytokine, comprises administering relaxin

INVENTOR: CONRAD, K P; HUANG, X ; LEWIS, M ; TOZZI, C A ; UNEMORI, E N

PRIORITY-DATA: 2000US-242216P (October 20, 2000), 2000US-181408P (February 9, 2000), 2000US-200284P (April 28, 2000), 2001US-0780752 (February 9, 2001)

PATENT-FAMILY:

LANGUAGE PAGES MAIN-IPC PUB-NO PUB-DATE 000 A61K038/00 February 14, 2002 US 2002019349 A1 A61K038/00 August 16, 2001 Ε 073 WO 200158468 A1 000 A61K038/00 August 20, 2001 AU 200136886 A

INT-CL (IPC): A61 K 38/00

Full Title Citation Front Review Classification Date Reference Sequences Attachments

KWC Draw Desc Image

Generate Collection

Print

Term	Documents
RELAXIN.DWPI,TDBD,EPAB,USPT,PGPB.	655
RELAXINS.DWPI,TDBD,EPAB,USPT,PGPB.	49
ISCHEMIC.DWPI,TDBD,EPAB,USPT,PGPB.	14176
ISCHEMICS.DWPI,TDBD,EPAB,USPT,PGPB.	20
WOUND.DWPI,TDBD,EPAB,USPT,PGPB.	353041
WOUNDS.DWPI,TDBD,EPAB,USPT,PGPB.	17941
(RELAXIN AND (ISCHEMIC SAME WOUND)).USPT,PGPB,EPAB,DWPI,TDBD.	11
(RELAXIN AND (ISCHEMIC SAME WOUND)).USPT,PGPB,EPAB,DWPI,TDBD.	11


Help Logout Interrupt

Main Menu Search Form Posting Counts Show S Numbers Edit S Numbers Preferences Cases

Search Results -

Term	Documents
RELAXIN.DWPI,TDBD,EPAB,USPT,PGPB.	655
RELAXINS.DWPI,TDBD,EPAB,USPT,PGPB.	49
STROKE?	0
STROKEA.DWPI,TDBD,EPAB,USPT,PGPB.	2
STROKEB.DWPI,TDBD,EPAB,USPT,PGPB.	1
STROKED.DWPI,TDBD,EPAB,USPT,PGPB.	2774
STROKEE.DWPI,TDBD,EPAB,USPT,PGPB.	10
STROKEL.DWPI,TDBD,EPAB,USPT,PGPB.	1
STROKEN.DWPI,TDBD,EPAB,USPT,PGPB.	10
STROKER.DWPI,TDBD,EPAB,USPT,PGPB.	187
STROKES.DWPI,TDBD,EPAB,USPT,PGPB.	39254
(RELAXIN AND STROKE?).USPT,PGPB,EPAB,DWPI,TDBD.	9

There are more results than shown above. Click here to view the entire set.



Search History

DATE: Wednesday, November 13, 2002 Printable Copy Create Case

Generate Collection

Print

Search Results - Record(s) 1 through 8 of 8 returned.

☐ 1. Document ID: US 20020151681 A1

L9: Entry 1 of 8

File: PGPB

Oct 17, 2002

PGPUB-DOCUMENT-NUMBER: 20020151681

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020151681 A1

TITLE: Nucleic acids, proteins and antibodies

PUBLICATION-DATE: October 17, 2002

INVENTOR-INFORMATION:

NAME

CITY

STATE

COUNTRY 1

RULE-47

Rosen, Craig A. Ruben, Steven M.

Olney

Full Title Citation Front Review Classification Date Reference Sequences Attachments

MD MD US US

US-CL-CURRENT: $\underline{530/350}$; $\underline{435/320.1}$, $\underline{435/325}$, $\underline{435/69.3}$, $\underline{536/23.5}$

Laytonsville

MMC Draw Desc Image

☐ 2. Document ID: US 20020122814 A1

L9: Entry 2 of 8

File: PGPB

Sep 5, 2002

PGPUB-DOCUMENT-NUMBER: 20020122814

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020122814 A1

TITLE: Uses for medical devices having a lubricious, nitric oxide-releasing coating

PUBLICATION-DATE: September 5, 2002

INVENTOR-INFORMATION:

NAME

CITY

STATE

COUNTRY RULE-47

Tedeschi, Eugene

Santa Rosa

CA

US

Shah, Chirag B.

North Attleboro

MA

US

US-CL-CURRENT: 424/426; 424/718, 427/2.24

Full Title Citation Front Review Classification Date Reference Sequences Attachments

KWMC Draw Desc Image

☐ 3. Document ID: US 20020045210 A1

L9: Entry 3 of 8

File: PGPB

Apr 18, 2002

PGPUB-DOCUMENT-NUMBER: 20020045210

PGPUB-FILING-TYPE: new

US

US

DOCUMENT-IDENTIFIER: US 20020045210 A1

TITLE: Neuropeptide-like polypeptide zpep17

PUBLICATION-DATE: April 18, 2002

INVENTOR - INFORMATION:

NAME

RULE-47 COUNTRY STATE CITY

Granite Falls WA Sheppard, Paull O. WA Bishop, Paul D. Fall City

US-CL-CURRENT: $\frac{435}{69.1}$; $\frac{435}{183}$, $\frac{435}{320.1}$, $\frac{435}{325}$, $\frac{536}{23.1}$

Full Title Citation Front Review Classification Date Reference Sequences Attachments

KWIC Draw Desc Image

☐ 4. Document ID: US 20020022046 A1

L9: Entry 4 of 8

File: PGPB

Feb 21, 2002

PGPUB-DOCUMENT-NUMBER: 20020022046

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020022046 A1

TITLE: USES FOR MEDICAL DEVICES HAVING A LUBRICIOUS, NITRIC OXIDE-RELEASING COATING

PUBLICATION-DATE: February 21, 2002

INVENTOR-INFORMATION:

STATE COUNTRY RULE-47 CITY NAME

CA US Tedeschi, Eugene Santa Rosa US Shah, Chirag B. North Attleboro MA

US-CL-CURRENT: 424/423

KNAC Draw Desc Image Full Title Citation Front Review Classification Date Reference Sequences Attachments

口 5. Document ID: US 20020019349 A1

L9: Entry 5 of 8

File: PGPB

Feb 14, 2002

PGPUB-DOCUMENT-NUMBER: 20020019349

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020019349 A1

TITLE: Use of relaxin treat diseases related to vasoconstriction

PUBLICATION-DATE: February 14, 2002

INVENTOR - INFORMATION:

COUNTRY STATE RULE-47 NAME CITY PΑ US Cranberry Township Conrad, Kirk P. Menlo park CA US Lewis, Martyn CA US Oakland Unemori, Elaine N. Menlo Park CA US Huang, Xinfan Jackson ИJ US Tozzi, Carol A.

US-CL-CURRENT: 514/12

Full Title Citation Front Review Classification Date Reference Sequences Attachments

KWiC Draw Desc Image

6. Document ID: US 20010021380 A1

L9: Entry 6 of 8

File: PGPB

Sep 13, 2001

PGPUB-DOCUMENT-NUMBER: 20010021380

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20010021380 A1

TITLE: Soluble tumor necrosis factor receptor treatment of medical disorders

PUBLICATION-DATE: September 13, 2001

INVENTOR-INFORMATION:

NAME

CITY

Full Title Citation Front Review Classification Date Reference Sequences Attachments

STATE

COUNTRY

RULE-47

Pluenneke, John D.

Kansas City MO

US

ZIP CODE

US-CL-CURRENT: 424/131.1; 514/171, 514/44

KWIC Draw Desc Image

7. Document ID: US 6379691 B1

L9: Entry 7 of 8

File: USPT

Apr 30, 2002

US-PAT-NO: 6379691

DOCUMENT-IDENTIFIER: US 6379691 B1

TITLE: Uses for medical devices having a lubricious, nitric oxide-releasing coating

DATE-ISSUED: April 30, 2002

INVENTOR-INFORMATION:

NAME

CITY

STATE

COUNTRY

Tedeschi; Eugene

Santa Rosa

CA

Shah; Chirag B.

Attleboro

MΑ

US-CL-CURRENT: 424/423; 424/422, 424/78.08, 514/824

Full Title Citation Front Review Classification Date Reference Sequences Attachments

KWC Draw. Desc Image

Note 10 September 10 Septemb

L9: Entry 8 of 8

File: DWPI

Feb 14, 2002

DERWENT-ACC-NO: 2001-514619

DERWENT-WEEK: 200214

COPYRIGHT 2002 DERWENT INFORMATION LTD

TITLE: Treating pulmonary or renal hypertension and an ischemic condition, increasing vasodilation and renal function, promoting wound healing and increasing production of angiogenic cytokine, comprises administering relaxin

INVENTOR: CONRAD, K P; HUANG, X ; LEWIS, M ; TOZZI, C A ; UNEMORI, E N

PRIORITY-DATA: 2000US-242216P (October 20, 2000), 2000US-181408P (February 9, 2000), 2000US-200284P (April 28, 2000), 2001US-0780752 (February 9, 2001)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
US 2002019349 A1	February 14, 2002		000	A61K038/00
WO 200158468 A1	August 16, 2001	E .	073	A61K038/00
AU 200136886 A	August 20, 2001		000	A61K038/00

INT-CL (IPC): $\underline{A61} \times \underline{38}/\underline{00}$

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KWMC	Drawa Desc	Image

Generate Collection

Print

Term	Documents
RELAXIN.DWPI,TDBD,EPAB,USPT,PGPB.	655
RELAXINS.DWPI,TDBD,EPAB,USPT,PGPB.	49
PULMONARY.DWPI,TDBD,EPAB,USPT,PGPB.	30215
PULMONARIES	0
PULMONARYS	0
HYPERTENSION.DWPI,TDBD,EPAB,USPT,PGPB.	31123
HYPERTENSIONS.DWPI,TDBD,EPAB,USPT,PGPB.	111
(RELAXIN AND (HYPERTENSION SAME PULMONARY)).USPT,PGPB,EPAB,DWPI,TDBD.	8
(RELAXIN AND (PULMONARY SAME HYPERTENSION)).USPT,PGPB,EPAB,DWPI,TDBD.	8

Display Format: -

Change Format

Previous Page

Next Page

Generate Collection

Print

Search Results - Record(s) 1 through 13 of 13 returned.

☐ 1. Document ID: US 20020031513 A1

L10: Entry 1 of 13

File: PGPB

Mar 14, 2002

PGPUB-DOCUMENT-NUMBER: 20020031513

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020031513 A1

TITLE: Method and pharmaceutical composition for inhibiting premature rapture of

fetal membranes, ripening of uterine cervix and preterm labor in mammals

PUBLICATION-DATE: March 14, 2002

INVENTOR-INFORMATION:

NAME

CITY

STATE

COUNTRY

RULE-47

Leibovitz, Shamir

Tel Aviv

II

US-CL-CURRENT: 424/141.1; 514/509, 514/562, 514/565, 514/575

Full Title Citation Front Review Classification Date Reference Sequences Attachments

KMMC Draw Desc Image

☐ 2. Document ID: US 20020019349 A1

L10: Entry 2 of 13

File: PGPB

Feb 14, 2002

PGPUB-DOCUMENT-NUMBER: 20020019349

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020019349 A1

TITLE: Use of relaxin treat diseases related to vasoconstriction

PUBLICATION-DATE: February 14, 2002

INVENTOR-INFORMATION:

COUNTRY RULE-47 STATE NAME CITY PA US Cranberry Township Conrad, Kirk P. US CA Menlo park Lewis, Martyn CA US Oakland Unemori, Elaine N. CA US Huang, Xinfan Menlo Park NJ US Tozzi, Carol A. Jackson

US-CL-CURRENT: 514/12

Full Title Citation Front Review Classification Date Reference Sequences Attachments

KMC Draw Desc Image

□ 3. Document ID: US 20010021380 A1

L10: Entry 3 of 13

File: PGPB

Sep 13, 2001

PGPUB-DOCUMENT-NUMBER: 20010021380

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20010021380 A1

TITLE: Soluble tumor necrosis factor receptor treatment of medical disorders

PUBLICATION-DATE: September 13, 2001

INVENTOR-INFORMATION:

NAME

CITY

STATE

COUNTRY

RULE-47

Pluenneke, John D.

Kansas City

MO

US

US-CL-CURRENT: 424/131.1; 514/171, 514/44

Full Title Citation Front Review Classification Date Reference Sequences Attachments

KWMC Draw Desc Image

☐ 4. Document ID: US 6468770 B1

L10: Entry 4 of 13

File: USPT

Oct 22, 2002

US-PAT-NO: 6468770

DOCUMENT-IDENTIFIER: US 6468770 B1

TITLE: Nucleic acids and proteins of D. melanogaster insulin-like genes and uses

thereof

DATE-ISSUED: October 22, 2002

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Keyes; Linda Nolan San Carlos CA
Doberstein; Stephen Kohl San Francisco CA
Buchman; Andrew Roy Berkeley CA
Reddy; Bindu Priya San Francisco CA

Ruddy; David Andrew San Francisco CA

US-CL-CURRENT: $\underline{435}/\underline{69.4}$; $\underline{435}/\underline{320.1}$, $\underline{435}/\underline{325}$, $\underline{435}/\underline{455}$, $\underline{435}/\underline{471}$, $\underline{435}/\underline{69.1}$, $\underline{536}/\underline{23.1}$,

536/23.5, 536/23.51

Full Title Citation Front Review Classification Date Reference Sequences Attachments

KMIC Draw Desc Image

5. Document ID: US 6410708 B1

L10: Entry 5 of 13

File: USPT

Jun 25, 2002

US-PAT-NO: 6410708

DOCUMENT-IDENTIFIER: US 6410708 B1

TITLE: Nucleic acids encoding A-33 related antigen polypeptides

DATE-ISSUED: June 25, 2002

INVENTOR-INFORMATION:

US-CL-CURRENT: $\underline{536}/\underline{23.5}$; $\underline{435}/\underline{252.3}$, $\underline{435}/\underline{252.33}$, $\underline{435}/\underline{254.2}$, $\underline{435}/\underline{320.1}$, $\underline{435}/\underline{348}$, 435/358, 435/455, 435/471, 435/69.1, 435/71.1, 435/71.2, 536/23.1

Full Title Citation Front Review Classification Date Reference Sequences Attachments

KMC Draw Desc Image

☐ 6. Document ID: US 6135942 A

L10: Entry 6 of 13

File: USPT

Oct 24, 2000

US-PAT-NO: 6135942

DOCUMENT-IDENTIFIER: US 6135942 A

TITLE: Nucleic acids proteins of a D. melanogaster insulin-like gene and uses

thereof

DATE-ISSUED: October 24, 2000

INVENTOR-INFORMATION:

NAME

CITY

STATE ZIP CODE

COUNTRY

Leptin; Maria

Cologne

US-CL-CURRENT: $\underline{536}/\underline{23.5}$; $\underline{435}/\underline{320.1}$, $\underline{435}/\underline{325}$, $\underline{435}/\underline{348}$, $\underline{435}/\underline{69.1}$, $\underline{435}/\underline{69.4}$

Full Title Citation Front Review Classification Date Reference Sequences Attachments

KWIC Draw Desc Image

☐ 7. Document ID: US 6114304 A

L10: Entry 7 of 13

File: USPT

Sep 5, 2000

US-PAT-NO: 6114304

DOCUMENT-IDENTIFIER: US 6114304 A

TITLE: Methods for regulating gastrointestinal motility

DATE-ISSUED: September 5, 2000

INVENTOR-INFORMATION:

NAME

Kolterman; Orville G. Young; Andrew A.

Rink; Timothy J.

Brown; Kathleen Ann Keiting

CITY

STATE ZIP CODE

COUNTRY

Poway

Alpine La Jolla

CA NC

CA

CA

Wake Forest

US-CL-CURRENT: 514/12; 514/3

Full Title Citation Front Review Classification Date Reference Sequences Attachments

KMAC Draw Desc Image

☐ 8. Document ID: US 5795861 A

L10: Entry 8 of 13

File: USPT

Aug 18, 1998

US-PAT-NO: 5795861

DOCUMENT-IDENTIFIER: US 5795861 A

TITLE: Methods for regulating gastrointestinal motility

DATE-ISSUED: August 18, 1998

INVENTOR-INFORMATION:

NAME

CITY

STATE ZIP CODE COUNTRY

Kolterman; Orville G.

Poway

CA

Rink; Timothy J.

La Jolla

CA

US-CL-CURRENT: 514/12; 514/11, 514/13, 514/866, 530/307, 530/327

Full Title Citation Front Review Classification Date Reference Sequences Attachments

KMAC Draw Desc Image

☐ 9. Document ID: US 5376638 A

L10: Entry 9 of 13

File: USPT

Dec 27, 1994

US-PAT-NO: 5376638

DOCUMENT-IDENTIFIER: US 5376638 A

TITLE: Methods for treating renin-related disorders with amylin antagonists

DATE-ISSUED: December 27, 1994

INVENTOR-INFORMATION:

NAME

CITY

STATE

COUNTRY

Young; Andrew A.

San Diego

CA

Rink; Timothy J.

La Jolla

CA

US-CL-CURRENT: 514/12; 514/11, 514/13

Full Title Citation Front Review Classification Date Reference Sequences Attachments

KMC Draw Desc Image

ZIP CODE

☐ 10. Document ID: US 5364841 A

L10: Entry 10 of 13

File: USPT

Nov 15, 1994

US-PAT-NO: 5364841

DOCUMENT-IDENTIFIER: US 5364841 A

TITLE: Treatment of obesity and essential hypertension and related disorders

DATE-ISSUED: November 15, 1994

INVENTOR-INFORMATION:

NAME

CITY

STATE ZIP CODE

COUNTRY

Cooper; Garth J. S.

Solana Beach

Leighton; Brendan

Eynsham

CA

GB2

US-CL-CURRENT: $\underline{514}/\underline{12}$; $\underline{514}/\underline{13}$, $\underline{514}/\underline{14}$, $\underline{514}/\underline{15}$, $\underline{514}/\underline{16}$, $\underline{514}/\underline{17}$, $\underline{514}/\underline{4}$

Full Title Citation Front Review Classification Date Reference Sequences Attachments

KWiC Draw Desc Image

☐ 11. Document ID: US 5280014 A

L10: Entry 11 of 13

File: USPT

Jan 18, 1994

US-PAT-NO: 5280014

DOCUMENT-IDENTIFIER: US 5280014 A

TITLE: Treatment of obesity and essential hypertension and related disorders

DATE-ISSUED: January 18, 1994

INVENTOR-INFORMATION:

NAME

CITY

Full Title Citation Front Review Classification Date Reference Sequences Attachments

STATE ZIP CODE COUNTRY

Cooper; Garth J. S.

Solana Beach

CA

Leighton; Brendan

Eynsham

GB2

KWIC Draw Deso Image

US-CL-CURRENT: $\underline{514}/\underline{12}$; $\underline{514}/\underline{13}$, $\underline{514}/\underline{14}$, $\underline{514}/\underline{15}$, $\underline{514}/\underline{16}$, $\underline{514}/\underline{17}$, $\underline{514}/\underline{4}$

☐ 12. Document ID: US 4423037 A

L10: Entry 12 of 13

File: USPT

Dec 27, 1983

US-PAT-NO: 4423037

DOCUMENT-IDENTIFIER: US 4423037 A

TITLE: Inhibitors of peptide hormone action

DATE-ISSUED: December 27, 1983

INVENTOR-INFORMATION:

NAME

CITY

STATE ZIP CODE

COUNTRY

Rosenblatt; Michael

Newton Highlands

MA

Potts, Jr.; John T.

West Newton

MA

US-CL-CURRENT: 514/12; 530/324, 530/334, 930/10, 930/20, 930/21, 930/DIG.821

Full Title Citation Front Review Classification Date Reference Sequences Attachments

KWIC Draw Desc Image

☐ 13. Document ID: US 2002019349 A1 WO 200158468 A1 AU 200136886 A

L10: Entry 13 of 13

File: DWPI

Feb 14, 2002

DERWENT-ACC-NO: 2001-514619

DERWENT-WEEK: 200214

COPYRIGHT 2002 DERWENT INFORMATION LTD TITLE: Treating pulmonary or renal hypertension and an ischemic condition, increasing vasodilation and $\underline{\text{renal}}$ function, promoting wound healing and increasing production of angiogenic cytokine, comprises administering $\underline{\text{relaxin}}$

INVENTOR: CONRAD, K P; HUANG, X ; LEWIS, M ; TOZZI, C A ; UNEMORI, E N

PRIORITY-DATA: 2000US-242216P (October 20, 2000), 2000US-181408P (February 9, 2000), 2000US-200284P (April 28, 2000), 2001US-0780752 (February 9, 2001)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
US 2002019349 A1	February 14, 2002		000	A61K038/00
WO 200158468 A1	August 16, 2001	E	073	A61K038/00
AU 200136886 A	August 20, 2001		000	A61K038/00

INT-CL (IPC): A61 K 38/00

Full Title Citation Front Review Classification Date Reference Sequences Attachments KMIC Draw Desc Im-														
	F	ull	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KWIC	Draw Desc	Image

Generate Collection

Print

Term	Documents
RELAXIN.DWPI,TDBD,EPAB,USPT,PGPB.	655
RELAXINS.DWPI,TDBD,EPAB,USPT,PGPB.	49
RENAL.DWPI,TDBD,EPAB,USPT,PGPB.	29674
RENALS.DWPI,TDBD,EPAB,USPT,PGPB.	69
HYPERTENSION.DWPI,TDBD,EPAB,USPT,PGPB.	31123
HYPERTENSIONS.DWPI,TDBD,EPAB,USPT,PGPB.	111
(RELAXIN AND (HYPERTENSION SAME RENAL)).USPT,PGPB,EPAB,DWPI,TDBD.	13
(RELAXIN AND (RENAL SAME HYPERTENSION)).USPT,PGPB,EPAB,DWPI,TDBD.	13

Display Format: -

Change Format

Previous Page

Next Page

Generate Collection

Print

Search Results - Record(s) 1 through 3 of 3 returned.

☐ 1. Document ID: US 20020045210 A1

L8: Entry 1 of 3

File: PGPB

Apr 18, 2002

PGPUB-DOCUMENT-NUMBER: 20020045210

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020045210 A1

TITLE: Neuropeptide-like polypeptide zpep17

PUBLICATION-DATE: April 18, 2002

INVENTOR-INFORMATION:

NAME CITY STATE COUNTRY RULE-47

Sheppard, Paull O. Granite Falls WA US Bishop, Paul D. Fall City WA US

US-CL-CURRENT: 435/69.1; 435/183, 435/320.1, 435/325, 536/23.1

Full Title Citation Front Review Classification Date Reference Sequences Attachments

KMC Draw Desc Image

☐ 2. Document ID: US 20020031513 A1

L8: Entry 2 of 3

File: PGPB

Mar 14, 2002

PGPUB-DOCUMENT-NUMBER: 20020031513

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020031513 A1

TITLE: Method and pharmaceutical composition for inhibiting premature rapture of fetal membranes, ripening of uterine cervix and preterm labor in mammals

PUBLICATION-DATE: March 14, 2002

INVENTOR-INFORMATION:

NAME

CITY

STATE

COUNTRY

RULE-47

Leibovitz, Shamir

Tel Aviv

IL

US-CL-CURRENT: 424/141.1; 514/509, 514/562, 514/565, 514/575

Full Title Citation Front Review Classification Date Reference Sequences Attachments

KMC Draw Desc Image

☐ 3. Document ID: US 5376638 A

L8: Entry 3 of 3

File: USPT

Dec 27, 1994

US-PAT-NO: 5376638

DOCUMENT-IDENTIFIER: US 5376638 A

TITLE: Methods for treating renin-related disorders with amylin antagonists

DATE-ISSUED: December 27, 1994

INVENTOR-INFORMATION:

NAME

CITY

STATE

ZIP CODE

COUNTRY

Young; Andrew A.

San Diego

CA

Rink; Timothy J.

La Jolla

CA

US-CL-CURRENT: 514/12; 514/11, 514/13

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments

KMC Draw Desc Image

Generate Collection

Print

Term	Documents
RELAXIN.DWPI,TDBD,EPAB,USPT,PGPB.	655
RELAXINS.DWPI,TDBD,EPAB,USPT,PGPB.	49
HYPERTENSION.DWPI,TDBD,EPAB,USPT,PGPB.	31123
HYPERTENSIONS.DWPI,TDBD,EPAB,USPT,PGPB.	111
RENAL.DWPI,TDBD,EPAB,USPT,PGPB.	29674
RENALS.DWPI,TDBD,EPAB,USPT,PGPB.	69
FUNCTION?	0
FUNCTIONA.DWPI,TDBD,EPAB,USPT,PGPB.	169
FUNCTIONB.DWPI,TDBD,EPAB,USPT,PGPB.	9
FUNCTIONC.DWPI,TDBD,EPAB,USPT,PGPB.	2
FUNCTIOND.DWPI,TDBD,EPAB,USPT,PGPB.	4
(RELAXIN AND HYPERTENSION AND (RENAL SAME FUNCTION?)).USPT,PGPB,EPAB,DWPI,TDBD.	3

There are more results than shown above. Click here to view the entire set.

Display Format: -

Change Format

Previous Page

Next Page

Generate Collection

Print

Search Results - Record(s) 1 through 2 of 2 returned.

☐ 1. Document ID: US 20020031513 A1

L7: Entry 1 of 2

File: PGPB

Mar 14, 2002

PGPUB-DOCUMENT-NUMBER: 20020031513

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020031513 A1

TITLE: Method and pharmaceutical composition for inhibiting premature rapture of

fetal membranes, ripening of uterine cervix and preterm labor in mammals

PUBLICATION-DATE: March 14, 2002

INVENTOR-INFORMATION:

NAME

CITY

STATE

COUNTRY

RULE-47

Leibovitz, Shamir

Tel Aviv

IL

US-CL-CURRENT: 424/141.1; 514/509, 514/562, 514/565, 514/575

Full Title Citation Front Review Classification Date Reference Sequences Attachments

KVVIC Draw Desc Image

☐ 2. Document ID: US 5376638 A

L7: Entry 2 of 2

File: USPT

Dec 27, 1994

US-PAT-NO: 5376638

DOCUMENT-IDENTIFIER: US 5376638 A

TITLE: Methods for treating renin-related disorders with amylin antagonists

DATE-ISSUED: December 27, 1994

INVENTOR-INFORMATION:

NAME

CITY

STATE

ZIP CODE

COUNTRY

Young; Andrew A.

San Diego

CA

Rink; Timothy J.

La Jolla

CA

US-CL-CURRENT: 514/12; 514/11, 514/13

Full Title Citation Front Review Classification Date Reference Sequences Attachments

KMC Draw Desc Image

Generate Collection

Print

Term	Documents
RELAXIN.DWPI,TDBD,EPAB,USPT,PGPB.	655
RELAXINS.DWPI,TDBD,EPAB,USPT,PGPB.	49
VASODILATION.DWPI,TDBD,EPAB,USPT,PGPB.	3926
VASODILATIONS.DWPI,TDBD,EPAB,USPT,PGPB.	11
HYPERTENSION.DWPI,TDBD,EPAB,USPT,PGPB.	31123
HYPERTENSIONS.DWPI,TDBD,EPAB,USPT,PGPB.	111
RENAL.DWPI,TDBD,EPAB,USPT,PGPB.	29674
RENALS.DWPI,TDBD,EPAB,USPT,PGPB.	69
VASODILATOR?	0
VASODILATORS.DWPI,TDBD,EPAB,USPT,PGPB.	5737
VASODILATORY.DWPI,TDBD,EPAB,USPT,PGPB.	1942
(RELAXIN AND (VASODILATION OR VASODILATOR?)AND HYPERTENSION AND (RENAL SAME FUNCTION?)).USPT,PGPB,EPAB,DWPI,TDBD.	2

There are more results than shown above. Click here to view the entire set.

Display Format:	-	Change Format
-----------------	---	---------------

Previous Page

Next Page

Generate Collection

Print

Search Results - Record(s) 1 through 47 of 47 returned.

☐ 1. Document ID: US 20020164372 A1

L5: Entry 1 of 47

File: PGPB

Nov 7, 2002

PGPUB-DOCUMENT-NUMBER: 20020164372

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020164372 A1

TITLE: Controlled release systems for polymers

PUBLICATION-DATE: November 7, 2002

INVENTOR-INFORMATION:

NAME

CITY

STATE

COUNTRY

RULE-47

Pestka, Sidney

North Caldwell

NJ

US

US-CL-CURRENT: 424/469; 514/2

Full Title Citation Front Review Classification Date Reference Sequences Attachments

KWIC Draw Desc Image

☐ 2. Document ID: US 20020122814 A1

L5: Entry 2 of 47

File: PGPB

Sep 5, 2002

PGPUB-DOCUMENT-NUMBER: 20020122814

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020122814 A1

TITLE: Uses for medical devices having a lubricious, nitric oxide-releasing coating

PUBLICATION-DATE: September 5, 2002

INVENTOR-INFORMATION:

NAME

CITY

STATE

RULE-47

Tedeschi, Eugene

Santa Rosa

CA

US

COUNTRY

Shah, Chirag B.

North Attleboro

MA

US

US-CL-CURRENT: 424/426; 424/718, 427/2.24

Full Title Citation Front Review Classification Date Reference Sequences Attachments

KNAC Draw, Desc Image

☐ 3. Document ID: US 20020068814 A1

L5: Entry 3 of 47

File: PGPB

Jun 6, 2002

PGPUB-DOCUMENT-NUMBER: 20020068814

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020068814 A1

STATE

COUNTRY

TITLE: Peptide antagonists of CGRP-receptor superfamily and methods of use

PUBLICATION-DATE: June 6, 2002

INVENTOR-INFORMATION:

CITY NAME

US NE Omaha Smith, Derek David US IN Indianapolis US Saha, Shankar NE Omaha

Abel, Peter W.

US-CL-CURRENT: 530/326; 435/7.1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments |

KMC Draw Desc Image

RULE-47

☐ 4. Document ID: US 20020031513 A1

Mar 14, 2002 File: PGPB L5: Entry 4 of 47

PGPUB-DOCUMENT-NUMBER: 20020031513

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020031513 A1

TITLE: Method and pharmaceutical composition for inhibiting premature rapture of

fetal membranes, ripening of uterine cervix and preterm labor in mammals

PUBLICATION-DATE: March 14, 2002

RULE-47 INVENTOR-INFORMATION: COUNTRY STATE CITY ILNAME

Tel Aviv Leibovitz, Shamir

US-CL-CURRENT: 424/141.1; 514/509, 514/562, 514/565, 514/575

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments |

KAMC Draw Desc Image

Feb 21, 2002

☐ 5. Document ID: US 20020022046 A1

File: PGPB L5: Entry 5 of 47

PGPUB-DOCUMENT-NUMBER: 20020022046

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020022046 A1

TITLE: USES FOR MEDICAL DEVICES HAVING A LUBRICIOUS, NITRIC OXIDE-RELEASING COATING

PUBLICATION-DATE: February 21, 2002

RULE-47 INVENTOR-INFORMATION: COUNTRY STATE CITY US CA

NAME Santa Rosa Tedeschi, Eugene US MA North Attleboro Shah, Chirag B.

US-CL-CURRENT: 424/423

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments |

KMC Drave Desc Image

☐ 6. Document ID: US 20020019349 A1

L5: Entry 6 of 47

File: PGPB

Feb 14, 2002

PGPUB-DOCUMENT-NUMBER: 20020019349

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020019349 A1

TITLE: Use of $\underline{\text{relaxin}}$ treat diseases related to vasoconstriction

PUBLICATION-DATE: February 14, 2002

INVENTOR-INFORMATION: NAME Conrad, Kirk P. Lewis, Martyn Unemori, Elaine N. Huang, Xinfan Tozzi, Carol A.	CITY Cranberry Township Menlo park Oakland Menlo Park Jackson	STATE PA CA CA CA NJ	COUNTRY US US US US US	RULE-47
---	---	----------------------	---------------------------------------	---------

US-CL-CURRENT: 514/12

									Ottoobroomts
					Classification	Date	Reference	Sequences	Affactiments 1
Full	Title	Citation	Front	Realism	Classification		7		Attachments

KMC Draw Desc Image

☐ 7. Document ID: US 20020010208 A1

L5: Entry 7 of 47

File: PGPB

Jan 24, 2002

PGPUB-DOCUMENT-NUMBER: 20020010208

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020010208 A1

TITLE: Dha-pharmaceutical agent conjugates of taxanes

PUBLICATION-DATE: January 24, 2002

INVENTOR-INFORMATION: NAME Shashoua, Victor Swindell, Charles Webb, Nigel Bradley, Matthews	CITY Brookline Merion Bryn Mawr Layton	STATE MA PA PA PA	COUNTRY US US US US	RULE-47
---	--	-------------------------------	---------------------------------	---------

US-CL-CURRENT: 514/449

									AH adapasts
				Pavierot	Classification	Date	Reference	Sequences	Attachments
Full	Title	Citation	Front	Neview					

KMC | Draw Desc | Image |

☐ 8. Document ID: US 20020004065 A1

Jan 10, 2002 File: PGPB L5: Entry 8 of 47

PGPUB-DOCUMENT-NUMBER: 20020004065

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020004065 A1

TITLE: Compositions and methods to effect the release profile in the transdermal administration of active agents

PUBLICATION-DATE: January 10, 2002

INVENTOR-INFORMATION:

NAME

CITY

STATE

COUNTRY

RULE-47

Kanios, David

Miami

FL

US

US-CL-CURRENT: 424/449

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments |

KWAC Draw Desc Image

☐ 9. Document ID: US 20010023254 A1

L5: Entry 9 of 47

File: PGPB

Sep 20, 2001

PGPUB-DOCUMENT-NUMBER: 20010023254

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20010023254 A1

TITLE: Use of sulfamate derivatives for treating impulse control disorders

PUBLICATION-DATE: September 20, 2001

INVENTOR-INFORMATION:

NAME

CITY

Full Title Citation Front Review Classification Date Reference Sequences Attachments

STATE

COUNTRY

RULE-47

McElroy, Susan L.

Cincinnati

OH

US

KMMC Draw Desc Image

US-CL-CURRENT: 514/439

☐ 10. Document ID: US 20010002404 A1

L5: Entry 10 of 47

File: PGPB

May 31, 2001

PGPUB-DOCUMENT-NUMBER: 20010002404

PGPUB-FILING-TYPE: new-utility

DOCUMENT-IDENTIFIER: US 20010002404 A1

TITLE: Fatty acid-pharmaceutical agent conjugates

PUBLICATION-DATE: May 31, 2001

INVENTOR-INFORMATION:

NAME Webb, Nigel L. CITY

STATE

COUNTRY RULE-47

Bryn Mawr Laytonsville

PA MD

US US

Bradley, Matthews O. Swindell, Charles S. Shashoua, Victor E.

Merion Brookline

PA MA US US

US-CL-CURRENT: 514/560; 514/558

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments |

KWIC Draw Desc Image

☐ 11. Document ID: US 6479630 B1

L5: Entry 11 of 47

File: USPT

Nov 12, 2002

US-PAT-NO: 6479630

DOCUMENT-IDENTIFIER: US 6479630 B1

TITLE: Human purinergic P2U receptor

DATE-ISSUED: November 12, 2002

INVENTOR-INFORMATION:

NAME

CITY

STATE ZIP CODE

COUNTRY

Coleman; Roger

Mountain View

CA

Au-Young; Janice

Berkeley Montara CA CA

Stuart; Susan G. Guegler; Karl J.

Menlo Park

CA

US-CL-CURRENT: 530/350; 530/326, 930/10

Full | Title | Citation | Front | Review | Classification | Data | Reterance | Sequences | Attachments

KMC Draw Desc Image

☐ 12. Document ID: US 6379691 B1

L5: Entry 12 of 47

File: USPT

Apr 30, 2002

US-PAT-NO: 6379691

DOCUMENT-IDENTIFIER: US 6379691 B1

TITLE: Uses for medical devices having a lubricious, nitric oxide-releasing coating

DATE-ISSUED: April 30, 2002

INVENTOR-INFORMATION:

NAME

CITY

STATE

ZIP CODE

COUNTRY

Tedeschi; Eugene

Santa Rosa

CA

Shah; Chirag B.

Attleboro

MA

US-CL-CURRENT: 424/423; 424/422, 424/78.08, 514/824

Full Title Citation Front Review Classification Date Reference Sequences Attachments

KMC Draw Desc Image

☐ 13. Document ID: US 6323236 B1

L5: Entry 13 of 47

File: USPT

Nov 27, 2001

US-PAT-NO: 6323236

DOCUMENT-IDENTIFIER: US 6323236 B1

TITLE: Use of sulfamate derivatives for treating impulse control disorders

DATE-ISSUED: November 27, 2001

INVENTOR-INFORMATION:

NAME

CITY

STATE

ZIP CODE

COUNTRY

McElroy; Susan

Cincinnati

OH

US-CL-CURRENT: 514/439; 514/455, 514/459, 514/463

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments

KWMC Draw Desc Image

☐ 14. Document ID: US 6268474 B1

L5: Entry 14 of 47

File: USPT

Jul 31, 2001

US-PAT-NO: 6268474

DOCUMENT-IDENTIFIER: US 6268474 B1

TITLE: Peptide antagonists of CGRP-receptor superfamily and methods of use

DATE-ISSUED: July 31, 2001

INVENTOR-INFORMATION:

NAME

CITY

STATE

ZIP CODE

COUNTRY

Smith; Derek David

Omaha

NE

COUNTRI

Saha; Shankar

Indianapolis

IN

Abel; Peter W.

Omaha

Full Title Citation Front Review Classification Date Reference Sequences Attachments

NE

US-CL-CURRENT: 530/326; 530/300, 530/307

KMC Draw Desc Image

☐ 15. Document ID: US 6258550 B1

L5: Entry 15 of 47

File: USPT

Jul 10, 2001

US-PAT-NO: 6258550

DOCUMENT-IDENTIFIER: US 6258550 B1

TITLE: Polypeptides that include conformation-constraining groups which flank a

protein-protein interaction site

DATE-ISSUED: July 10, 2001

INVENTOR-INFORMATION:

NAME

CITY

STATE

ZIP CODE COUNTRY

Evans; Herbert J.

Richmond

VA

SG

Kini; R. Manjunatha Singapore

US-CL-CURRENT: 435/7.1; 435/183, 530/300

Full Title Citation Front Review Classification Date Reference Sequences Attachments

KWIC Draw Desc Image

☐ 16. Document ID: US 6221383 B1

L5: Entry 16 of 47

File: USPT

Apr 24, 2001

US-PAT-NO: 6221383

Record List Display

DOCUMENT-IDENTIFIER: US 6221383 B1

TITLE: Solubility parameter based drug delivery system and method for altering drug

saturation concentration

DATE-ISSUED: April 24, 2001

INVENTOR - INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Miranda; Jesus Miami FL Sablotsky; Steven Miami FL

US-CL-CURRENT: 424/449; 424/448

Full Title Citation Front Review Classification Date Reference Sequences Attachments

KMC Draw Desc Image

☐ 17. Document ID: US 6147189 A

L5: Entry 17 of 47

File: USPT

Nov 14, 2000

US-PAT-NO: 6147189

DOCUMENT-IDENTIFIER: US 6147189 A

TITLE: Polypeptides that include conformation-constraining groups which flank a

protein-protein interaction site

DATE-ISSUED: November 14, 2000

INVENTOR - INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Evans; Herbert J. Richmond VA

Kini; R. Manjunatha Singapore SG

US-CL-CURRENT: 530/333; 530/328, 548/533

Full Title Citation Front Review Classification Date Reference Sequences Attachments KMIC Draw Desc Image

☐ 18. Document ID: US 6114304 A

L5: Entry 18 of 47

File: USPT

Sep 5, 2000

US-PAT-NO: 6114304

DOCUMENT-IDENTIFIER: US 6114304 A

TITLE: Methods for regulating gastrointestinal motility

DATE-ISSUED: September 5, 2000

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Kolterman; Orville G. Poway CA
Young; Andrew A. Alpine CA
Rink; Timothy J. La Jolla CA
Brown; Kathleen Ann Keiting Wake Forest NC

US-CL-CURRENT: 514/12; 514/3

Full Title Citation Front Review Classification Date Reference Sequences Attachments

KWIC Draw Desc Image

☐ 19. Document ID: US 6111069 A

L5: Entry 19 of 47

File: USPT

Aug 29, 2000

US-PAT-NO: 6111069

DOCUMENT-IDENTIFIER: US 6111069 A

TITLE: Polypeptides that include conformation-constraining groups which flank a protein-protein interaction site

DATE-ISSUED: August 29, 2000

INVENTOR-INFORMATION:

NAME

CITY

STATE

ZIP CODE

COUNTRY

Evans; Herbert J. Kini; R. Manjunatha Richmond Singapore

VA

SG

US-CL-CURRENT: 530/333; 530/328, 548/533

Full Title Citation Front Review Classification Date Reference Sequences Attachments

KWAC | Draw Desc | Image |

☐ 20. Document ID: US 6100044 A

L5: Entry 20 of 47

File: USPT

Aug 8, 2000

US-PAT-NO: 6100044

DOCUMENT-IDENTIFIER: US 6100044 A

TITLE: Polypeptides that include conformation-constraining groups which flank a protein-protein interaction site

DATE-ISSUED: August 8, 2000

INVENTOR-INFORMATION:

NAME

CITY

STATE

ZIP CODE

COUNTRY

Evans; Herbert J.

Richmond

VA

Kini; R. Manjunatha

Singapore

SG

US-CL-CURRENT: 435/7.1; 436/501, 514/12, 514/13, 514/2, 548/533

Full Title Citation Front Review Classification Date Reference Sequences Attachments

KMC Draw, Desc Image

☐ 21. Document ID: US 6084066 A

L5: Entry 21 of 47

File: USPT

Jul 4, 2000

US-PAT-NO: 6084066

DOCUMENT-IDENTIFIER: US 6084066 A

TITLE: Polypetides that include conformation-constraining groups which flank a protein-protein interaction site

DATE-ISSUED: July 4, 2000

INVENTOR - INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Evans; Herbert J. Richmond VA

Kini; R. Manjunatha Singapore IN

US-CL-CURRENT: 530/333; 530/329, 548/533

Full Title Citation Front Review Classification Date Reference Sequences Attachments KMIC Draw Desc Image

☐ 22. Document ID: US 6075005 A

L5: Entry 22 of 47 File: USPT

Jun 13, 2000

US-PAT-NO: 6075005

DOCUMENT-IDENTIFIER: US 6075005 A

TITLE: Medicaments comprising relaxin and their use

DATE-ISSUED: June 13, 2000

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Lurie; Raziel Tel Aviv IL

US-CL-CURRENT: 514/2; 514/275, 514/284

Full Title Citation Front Review Classification Date Reference Sequences Attachments KMC Draw Desc Image

☐ 23. Document ID: US 6024976 A

L5: Entry 23 of 47 File: USPT Feb 15, 2000

US-PAT-NO: 6024976

DOCUMENT-IDENTIFIER: US 6024976 A

TITLE: Solubility parameter based drug delivery system and method for altering drug

saturation concentration

DATE-ISSUED: February 15, 2000

INVENTOR - INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Miranda; Jesus Miami FL Sablotsky; Steven Miami FL

US-CL-CURRENT: 424/449; 424/448

Full Title Citation Front Review Classification Date Reference Sequences Attachments

☐ 24. Document ID: US 6008039 A

Record List Display

L5: Entry 24 of 47

File: USPT

Dec 28, 1999

US-PAT-NO: 6008039

DOCUMENT-IDENTIFIER: US 6008039 A

TITLE: Polynucleotide encoding a novel purinergic P.sub.2U receptor

DATE-ISSUED: December 28, 1999

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Coleman; Roger Mountain View CA
Au-Young; Janice Berkeley CA
Stuart; Susan G. Montara CA
Guegler; Karl J. Menlo Park CA

US-CL-CURRENT: 435/325; 435/320.1, 435/91.2, 536/23.1, 536/23.5

Full Title Citation Front Review Classification Date Reference Sequences Attachments KMC Draw Desc Image

☐ 25. Document ID: US 5972894 A

L5: Entry 25 of 47

File: USPT

Oct 26, 1999

US-PAT-NO: 5972894

DOCUMENT-IDENTIFIER: US 5972894 A

TITLE: Peptides having potassium channel opener activity

DATE-ISSUED: October 26, 1999

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Sinackevich; Nickolai V. St. Petersburg RU
Rakhilov; Alexi M. St. Petersburg RU
Maslennikov; Sergei V. St. Petersburg RU

Green; Lawrence R. Tacoma WA

US-CL-CURRENT: 514/16; 514/19

Full Title Citation Front Review Classification Date Reference Sequences Attachments KMIC Draw Desc Image

26. Document ID: US 5965698 A

L5: Entry 26 of 47

File: USPT

Oct 12, 1999

US-PAT-NO: 5965698

DOCUMENT-IDENTIFIER: US 5965698 A

TITLE: Polypeptides that include conformation-constraining groups which flank a protein--protein interaction site

DATE-ISSUED: October 12, 1999

INVENTOR - INFORMATION:

NAME

CITY

ZIP CODE STATE

COUNTRY

Evans; Herbert J.

Richmond

Kini; R. Manjunatha

Singapore

SG

US-CL-CURRENT: $\frac{530}{326}$; $\frac{530}{300}$, $\frac{530}{324}$, $\frac{530}{333}$, $\frac{530}{380}$, $\frac{548}{533}$

Full Title Citation Front Review Classification Date Reference Sequences Attachments

KWIC Draw Desc Image

☐ 27. Document ID: US 5955284 A

L5: Entry 27 of 47

File: USPT

VA

Sep 21, 1999

US-PAT-NO: 5955284

DOCUMENT-IDENTIFIER: US 5955284 A

TITLE: Assay method to detect serpin derived from human hypothalamus

DATE-ISSUED: September 21, 1999

INVENTOR-INFORMATION:

NAME

CITY

ZIP CODE STATE

COUNTRY

Braxton; Scott Michael

San Mateo

San Francisco

CA CA

Diep; Dinh Stuart; Susan G.

Montara

CA

US-CL-CURRENT: 435/6; 536/23.1, 536/24.31

Full Title Citation Front Review Classification Date Reference Sequences Attachments

KMC Draw, Desc Image

☐ 28. Document ID: US 5952465 A

L5: Entry 28 of 47

File: USPT

Sep 14, 1999

US-PAT-NO: 5952465

DOCUMENT-IDENTIFIER: US 5952465 A

TITLE: Polypeptides that include conformation-constraining groups which flank a

US-CL-CURRENT: 530/333; 424/185.1, 424/278.1, 530/326, 530/327, 530/328, 548/533

protein-protein interaction site

DATE-ISSUED: September 14, 1999

INVENTOR-INFORMATION:

NAME

CITY

STATE

ZIP CODE

COUNTRY

Evans; Herbert J.

Richmond

VA

SG

Kini; R. Manjunatha Singapore

Full Title Citation Front Review Classification Date Reference Sequences Attachments

KMC Draw Desc Image

☐ 29. Document ID: US 5952296 A

L5: Entry 29 of 47

File: USPT

Sep 14, 1999

US-PAT-NO: 5952296

DOCUMENT-IDENTIFIER: US 5952296 A

TITLE: Method of using relaxin as therapeutic or preventing agent

DATE-ISSUED: September 14, 1999

INVENTOR - INFORMATION:

NAME

CITY

STATE

ZIP CODE

COUNTRY

Bigazzi; Mario

Florence

Full Title Citation Front Review Classification Date Reference Sequences Attachments

IT

KWIC Draw Desc Image

US-CL-CURRENT: 514/3; 514/12, 514/822, 514/885

30. Document ID: US 5948887 A

L5: Entry 30 of 47

File: USPT

Sep 7, 1999

US-PAT-NO: 5948887

DOCUMENT-IDENTIFIER: US 5948887 A

TITLE: Polypeptides that include conformation-constraining groups which flank a

protein--protein interaction site

DATE-ISSUED: September 7, 1999

INVENTOR-INFORMATION:

Kini; R. Manjunatha

NAME

CITY

STATE

ZIP CODE

COUNTRY

Evans; Herbert J.

Richmond Singapore VA

SG

US-CL-CURRENT: 530/333; 548/533

Full Title Citation Front Review Classification Date Reference Sequences Attachments

KMC Draw Desc Image

☐ 31. Document ID: US 5929210 A

L5: Entry 31 of 47

File: USPT

Jul 27, 1999

US-PAT-NO: 5929210

DOCUMENT-IDENTIFIER: US 5929210 A

TITLE: Serpin derived from human hypothalmus

DATE-ISSUED: July 27, 1999

INVENTOR-INFORMATION:

NAME

CITY

STATE ZIP CODE

COUNTRY

Braxton; Scott Michael

San Mateo

CA

Diep; Dinh

San Francisco

CA

Stuart; Susan G.

Montara

CA

US-CL-CURRENT: 530/350

Full Title Citation Front Review Classification Date Reference Sequences Attachments

KMIC Draw Desc Image

☐ 32. Document ID: US 5928896 A

L5: Entry 32 of 47

File: USPT

Jul 27, 1999

US-PAT-NO: 5928896

DOCUMENT-IDENTIFIER: US 5928896 A

TITLE: Polypeptides that include conformation-constraining groups which flank a

protein--protein interaction site

DATE-ISSUED: July 27, 1999

INVENTOR - INFORMATION:

NAME

CITY

STATE

ZIP CODE

COUNTRY

Evans; Herbert J.

Richmond

VA

Kini; R. Manjunatha

Singapore

SG

KMC Draw Desc Image

US-CL-CURRENT: 435/69.1; 435/91.2, 530/300, 530/324

Full Title Citation Front Review Classification Date Reference Sequences Attachments

□ 33. Document ID: US 5795909 A

L5: Entry 33 of 47

File: USPT

Aug 18, 1998

US-PAT-NO: 5795909

DOCUMENT-IDENTIFIER: US 5795909 A

TITLE: DHA-pharmaceutical agent conjugates of taxanes

DATE-ISSUED: August 18, 1998

INVENTOR-INFORMATION:

NAME

CITY

STATE ZIP CODE COUNTRY

Shashoua; Victor E.

Brookline

MA

Swindell; Charles S.

Merion

PA

Webb; Nigel L.

Bryn Mawr

Bradley; Matthews O.

Laytonsville

PA MD

US-CL-CURRENT: 514/449; 514/549

Full Title Citation Front Review Classification Date Reference Sequences Attachments

KNMC Draws Desc Image

☐ 34. Document ID: US 5795861 A

L5: Entry 34 of 47

File: USPT

Aug 18, 1998

US-PAT-NO: 5795861

DOCUMENT-IDENTIFIER: US 5795861 A

TITLE: Methods for regulating gastrointestinal motility

DATE-ISSUED: August 18, 1998

INVENTOR - INFORMATION:

NAME

CITY

ZIP CODE

COUNTRY

Kolterman; Orville G.

Poway

STATE CA

Rink; Timothy J.

La Jolla

CA

US-CL-CURRENT: 514/12; 514/11, 514/13, 514/866, 530/307, 530/327

Full Title Citation Front Review Classification Date Reference Sequences Attachments

KAMC Draw Desc Image

☐ 35. Document ID: US 5719197 A

L5: Entry 35 of 47

File: USPT

Feb 17, 1998

US-PAT-NO: 5719197

DOCUMENT-IDENTIFIER: US 5719197 A

TITLE: Compositions and methods for topical administration of pharmaceutically

active agents

DATE-ISSUED: February 17, 1998

INVENTOR-INFORMATION:

NAME

CITY

STATE

ZIP CODE

COUNTRY

Kanios; David P.

Miami

FL

Gentile; Joseph A.

Plantation Miami

FLFL

Mantelle; Juan A. Sablotsky; Steven

Miami

FL

US-CL-CURRENT: 514/772.6; 424/435, 424/443, 514/781, 514/782

Full Title Citation Front Review Classification Date Reference Sequences Attachments

KVMC Draw Desc Image

☐ 36. Document ID: US 5700924 A

L5: Entry 36 of 47

File: USPT

Dec 23, 1997

US-PAT-NO: 5700924

DOCUMENT-IDENTIFIER: US 5700924 A

TITLE: Serpin derived from human hypothalamus

DATE-ISSUED: December 23, 1997

INVENTOR - INFORMATION:

NAME

CITY

ZIP CODE STATE

COUNTRY

Braxton; Scott Michael

San Mateo

CA

Diep; Dinh

San Francisco

CA

Stuart; Susan G.

Montara

CA

US-CL-CURRENT: 536/23.1; 435/320.1, 435/69.1, 435/91.4

Full Title Citation Front Review Classification Date Reference Sequences Attachments

KWAC | Draw Desc | Image |

☐ 37. Document ID: US 5677279 A

L5: Entry 37 of 47

File: USPT

Oct 14, 1997

US-PAT-NO: 5677279

DOCUMENT-IDENTIFIER: US 5677279 A

TITLE: Methods and compositions for treating pain with amylin or agonists thereof

DATE-ISSUED: October 14, 1997

INVENTOR-INFORMATION:

NAME

CITY

STATE

ZIP CODE

COUNTRY

Young; Andrew A.

San Diego

CA

US-CL-CURRENT: 514/12

Full Title Citation Front Review Classification Date Reference Sequences Attachments

KMC Draw Desc Image

☐ 38. Document ID: US 5656286 A

L5: Entry 38 of 47

File: USPT

Aug 12, 1997

US-PAT-NO: 5656286

DOCUMENT-IDENTIFIER: US 5656286 A

TITLE: Solubility parameter based drug delivery system and method for altering drug

saturation concentration

DATE-ISSUED: August 12, 1997

INVENTOR-INFORMATION:

NAME

CITY

STATE

ZIP CODE

COUNTRY

Miranda; Jesus

Miami

FL

Sablotsky; Steven

Miami

FL

US-CL-CURRENT: 424/449; 424/448

Full Title Citation Front Review Classification Date Reference Sequences Attachments

KMC Draw Desc Image

☐ 39. Document ID: US 5637309 A

L5: Entry 39 of 47

File: USPT

Jun 10, 1997

US-PAT-NO: 5637309

DOCUMENT-IDENTIFIER: US 5637309 A

TITLE: Physiologically active substance-prolonged releasing-type pharmaceutical

preparation

DATE-ISSUED: June 10, 1997

INVENTOR-INFORMATION:

Y STATE ZIP CODE COUNTRY
ohama JP
dai JP
ohama JP
ohama JP
yo JP
ohama JP
ohama JP

US-CL-CURRENT: $\frac{424}{423}$; $\frac{424}{426}$, $\frac{424}{457}$, $\frac{424}{468}$, $\frac{514}{772.3}$, $\frac{514}{777}$, $\frac{514}{781}$, $\frac{514}{784}$, $\frac{514}{785}$, $\frac{514}{808}$, $\frac{514}{929}$

Full Title Citation Front Review Classification Date Reference Sequences Attachments

KMC Draw Desc Image

☐ 40. Document ID: US 5478807 A

L5: Entry 40 of 47

File: USPT

Dec 26, 1995

US-PAT-NO: 5478807

DOCUMENT-IDENTIFIER: US 5478807 A

TITLE: Use of relaxin in the treatment of bradycardia

DATE-ISSUED: December 26, 1995

INVENTOR-INFORMATION:

NAME

CITY

STATE ZIP CODE

COUNTRY

Cronin; Michael Osheroff; Phyllis L. San Mateo Woodside CA CA

Thomas; G. Roger

Burlingame

CA

Ward; David G.

Oakdale

CA

US-CL-CURRENT: 514/12; 530/324

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments |

KWIC Draw Desc Image

1 41. Document ID: US 5446070 A

L5: Entry 41 of 47

File: USPT

Aug 29, 1995

US-PAT-NO: 5446070

DOCUMENT-IDENTIFIER: US 5446070 A

TITLE: Compositions and methods for topical administration of pharmaceutically

active agents

DATE-ISSUED: August 29, 1995

INVENTOR-INFORMATION:

NAME

CITY

ZIP CODE

COUNTRY

Mantelle; Juan A.

Miami

STATE FL

US-CL-CURRENT: 514/772.6; 424/485, 424/486, 424/487, 424/488, 514/781, 514/782

Full Title Citation Front Review Classification Date Reference Sequences Attachments

KWoiC Draw Desc Image

☐ 42. Document ID: US 5376638 A

L5: Entry 42 of 47

File: USPT

Dec 27, 1994

US-PAT-NO: 5376638

DOCUMENT-IDENTIFIER: US 5376638 A

TITLE: Methods for treating renin-related disorders with amylin antagonists

DATE-ISSUED: December 27, 1994

INVENTOR-INFORMATION:

NAME CITY

San Diego

STATE ZIP CODE

COUNTRY

Young; Andrew A. Rink; Timothy J.

La Jolla

CA CA

US-CL-CURRENT: 514/12; 514/11, 514/13

Full Title Citation Front Review Classification Date Reference Sequences Attachments

KMC Draw Desc Image

☐ 43. Document ID: US 5288623 A

L5: Entry 43 of 47

File: USPT

Feb 22, 1994

US-PAT-NO: 5288623

DOCUMENT-IDENTIFIER: US 5288623 A

TITLE: Process for secretory production of a calcium-binding protein

DATE-ISSUED: February 22, 1994

INVENTOR-INFORMATION:

NAME

CITY

STATE

ZIP CODE

COUNTRY

Zenno; Shuhei

Yokohama

JP

Inouye; Satoshi

San Diego

CA

US-CL-CURRENT: 435/69.7; 435/252.3, 435/320.1

Full Title Citation Front Review Classification Date Reference Sequences Attachments

KWIC Draw Desc Image

☐ 44. Document ID: US 5264372 A

L5: Entry 44 of 47

File: USPT

Nov 23, 1993

US-PAT-NO: 5264372

DOCUMENT-IDENTIFIER: US 5264372 A

TITLE: Receptor-based screening methods for amylin agonists and antagonists

DATE-ISSUED: November 23, 1993

INVENTOR-INFORMATION:

NAME

CITY

Full Title Citation Front Review Classification Date Reference Sequences Attachments

ZIP CODE

COUNTRY

Beaumont; Kevin

San Diego

STATE

Rink; Timothy J.

San Diego

CA CA

US-CL-CURRENT: 436/504; 436/501, 436/503

KWiC Draw Desc Image

☐ 45. Document ID: US 5166191 A

L5: Entry 45 of 47

File: USPT

Nov 24, 1992

US-PAT-NO: 5166191

DOCUMENT-IDENTIFIER: US 5166191 A

TITLE: Use of relaxin in cardiovascular therapy

DATE-ISSUED: November 24, 1992

INVENTOR-INFORMATION:

NAME

CITY

STATE

ZIP CODE

COUNTRY

Cronin; Michael

San Mateo

CA

Osheroff; Phyllis L. Ward; David G.

Woodside Oakdale

CA CA

US-CL-CURRENT: 514/12; 530/324

Full Title Citation Front Review Classification Date Reference Sequences Attachments

KWIC Drawi Desc Image

46. Document ID: US 2002019349 A1 WO 200158468 A1 AU 200136886 A

L5: Entry 46 of 47

File: DWPI

Feb 14, 2002

DERWENT-ACC-NO: 2001-514619

DERWENT-WEEK: 200214

COPYRIGHT 2002 DERWENT INFORMATION LTD

TITLE: Treating pulmonary or renal hypertension and an ischemic condition,

increasing vasodilation and renal function, promoting wound healing and increasing

production of angiogenic cytokine, comprises administering relaxin

INVENTOR: CONRAD, K P; HUANG, X ; LEWIS, M ; TOZZI, C A ; UNEMORI, E N

PRIORITY-DATA: 2000US-242216P (October 20, 2000), 2000US-181408P (February 9, 2000),

2000US-200284P (April 28, 2000), 2001US-0780752 (February 9, 2001)

PATENT-FAMILY:

PUB-DATE LANGUAGE PAGES MAIN-IPC PUR-NO 000 A61K038/00 US 2002019349 A1 February 14, 2002 073 A61K038/00 August 16, 2001 Ε WO 200158468 A1 000 A61K038/00 August 20, 2001 AU 200136886 A

INT-CL (IPC): A61 K 38/00

Full Title Citation Front Review Classification Date Reference Sequences Attachments

KNNC Draw Desc Image

1 47. Document ID: US 2001002404 A1

L5: Entry 47 of 47

File: DWPI

May 31, 2001

DERWENT-ACC-NO: 2001-366605

DERWENT-WEEK: 200138

COPYRIGHT 2002 DERWENT INFORMATION LTD

TITLE: Targeting pharmaceutical agents to non-central nervous system tissues to treat e.g. psoriasis by administering covalent conjugates of unbranched naturally

occurring fatty acid and pharmaceutical agent

INVENTOR: BRADLEY, M O; SHASHOUA, V E; SWINDELL, C S; WEBB, N L

PRIORITY-DATA: 1996US-0651428 (May 22, 1996), 2000US-0730450 (December 5, 2000)

PATENT-FAMILY:

PUB-NO

PUB-DATE

LANGUAGE

PAGES

MAIN-IPC

US 2001002404 A1

May 31, 2001

043

A61K031/20

INT-CL (IPC): A61 K 31/20

Full Title Citation Front Review Classification Date Reference Sequences Attachments

Killic Draw Desc Image

Generate Collection

Print

Term	Documents
RELAXIN.DWPI,TDBD,EPAB,USPT,PGPB.	655
RELAXINS.DWPI,TDBD,EPAB,USPT,PGPB.	49
VASODILATION.DWPI,TDBD,EPAB,USPT,PGPB.	3926
VASODILATIONS.DWPI,TDBD,EPAB,USPT,PGPB.	11
VASODILATOR?	0
VASODILATORS.DWPI,TDBD,EPAB,USPT,PGPB.	5737
VASODILATORY.DWPI,TDBD,EPAB,USPT,PGPB.	1942
VASODILATOR:.DWPI,TDBD,EPAB,USPT,PGPB.	9
(RELAXIN AND (VASODILATION OR VASODILATOR?)).USPT,PGPB,EPAB,DWPI,TDBD.	47
(RELAXIN AND (VASODILATION OR VASODILATOR?)).USPT,PGPB,EPAB,DWPI,TDBD.	47

Display Format: | -

Change Format

Previous Page

Next Page

WEST Search History

DATE: Wednesday, November 13, 2002

Set Name	Query	Hit Count S	
side by side			result set
	SPT,PGPB,EPAB,DWPI,TDBD; THES=ASSIGNEE; PLUR=YES;		
OP = ADJ			
L13	relaxin and stroke?	9	L13
L12	relaxin and (ischemic same cardiac)	10	L12
L11	relaxin and (ischemic same wound)	11	L11
L10	relaxin and (renal same hypertension)	13	L10
L9	relaxin and (pulmonary same hypertension)	8	L9
L8	relaxin and hypertension and (renal same function?)	3	L8
L7	relaxin and (vasodilation or vasodilator?) and hypertension and (renal same function?)	2	L7
L6	relaxin and (vasodilation or vasodilator?) and hypertension	17	L6
L5	relaxin and (vasodilation or vasodilator?)	47	L5
L4	5166191.pn.	2	L4
L3	08050745.ap.	0	L3
L2	unemori-elaine.in.	7	L2
L1	unemori-elaine-n\$.in.	1	L1

END OF SEARCH HISTORY

FILE 'HOME' ENTERED AT 16:07:32 ON 13 NOV 2002

=> index medicine bioscience meetings
FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED

COST IN U.S. DOLLARS

SINCE FILE TOTAL ENTRY SESSION

FULL ESTIMATED COST

1.26 1.26

INDEX 'ADISALERTS, ADISINSIGHT, ADISNEWS, BIOSIS, BIOTECHNO, CANCERLIT, CAPLUS, CEN, DDFB, DDFU, DGENE, DRUGB, DRUGLAUNCH, DRUGMONOG2, DRUGNL, DRUGU, EMBAL, EMBASE, ESBIOBASE, IFIPAT, IPA, JICST-EPLUS, KOSMET, LIFESCI, MEDICONF, MEDLINE, NAPRALERT, NLDB, ...' ENTERED AT 16:10:47 ON 13 NOV 2002

78 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term postings or to view search error messages that display as 0* with SET DETAIL OFF.

=> s (relaxin same recombinant or relaxin) and hypertension and (ischemic or ischemia) and vasodilation

- 1 FILE CAPLUS
- 26 FILE DGENE
- 16 FILES SEARCHED...
 - 2 FILE IFIPAT
- 30 FILES SEARCHED...
 - 5 FILE USPATFULL
 - 1 FILE USPAT2
- 48 FILES SEARCHED...
 - 1 FILE WPIDS
- 66 FILES SEARCHED...
 - 1 FILE WPINDEX

7 FILES HAVE ONE OR MORE ANSWERS, 78 FILES SEARCHED IN STNINDEX

L1 QUE (RELAXIN SAME RECOMBINANT OR RELAXIN) AND HYPERTENSION AND (ISCHEMIC O R ISCHEMIA) AND VASODILATION

=> file hits

COST IN U.S. DOLLARS

SINCE FILE TOTAL ENTRY SESSION 13.78 15.04

FULL ESTIMATED COST

FILE 'DGENE' ENTERED AT 16:26:19 ON 13 NOV 2002 COPYRIGHT (C) 2002 THOMSON DERWENT

FILE 'USPATFULL' ENTERED AT 16:26:19 ON 13 NOV 2002 CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'IFIPAT' ENTERED AT 16:26:19 ON 13 NOV 2002 COPYRIGHT (C) 2002 IFI CLAIMS(R) Patent Services (IFI)

FILE 'CAPLUS' ENTERED AT 16:26:19 ON 13 NOV 2002 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 16:26:19 ON 13 NOV 2002 CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ENTERED AT 16:26:19 ON 13 NOV 2002 COPYRIGHT (C) 2002 THOMSON DERWENT

FILE 'WPINDEX' ACCESS NOT AUTHORIZED

=> s 11

L2 26 FILE DGENE

L3 5 FILE USPATFULL
L4 2 FILE IFIPAT
L5 1 FILE CAPLUS
L6 1 FILE USPAT2
L7 1 FILE WPIDS

TOTAL FOR ALL FILES L8 36 L1

=> dup rem 18

DUPLICATE IS NOT AVAILABLE IN 'DGENE'.

ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE

PROCESSING COMPLETED FOR L8

L9 32 DUP REM L8 (4 DUPLICATES REMOVED)

=> d 19 1-32 ibib abs

L9 ANSWER 1 OF 32 USPATFULL

DUPLICATE 1

ACCESSION NUMBER:

2002:37330 USPATFULL

TITLE:

USES FOR MEDICAL DEVICES HAVING A LUBRICIOUS, NITRIC

OXIDE-RELEASING COATING

INVENTOR(S):

Tedeschi, Eugene, Santa Rosa, CA, UNITED STATES Shah, Chirag B., North Attleboro, MA, UNITED STATES

PATENT ASSIGNEE(S):

Arterial Vascular Engineering, Inc. (U.S. corporation)

RELATED APPLN. INFO.:

Continuation-in-part of Ser. No. US 1999-405024, filed

on 27 Sep 1999, GRANTED, Pat. No. US 6218016

Continuation-in-part of Ser. No. US 1998-163038, filed

on 29 Sep 1998, GRANTED, Pat. No. US 6299980

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION

FILE SEGMENT: LEGAL REPRESENTATIVE:

MEDTRONIC AVE, INC., 3576 UNOCAL PLACE, SANTA ROSA, CA,

95403

NUMBER OF CLAIMS: 15
EXEMPLARY CLAIM: 1
LINE COUNT: 1240

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

Methods are provided for delivering nitric oxide to the vascular tissue of a patient to inhibit or prevent restenosis or improve vascular function following various surgical procedures or associated with various NO-related conditions. The disclosed methods comprise contacting the vascular tissue of a patient with a medical device coated with a coating comprising nitric oxide associated with and releaseable from a polyurea network formed from the reaction on said medical device of a polyisocyanate; an amine donor and/or hydroxyl donor; an isocyanatosilane adduct having terminal isocyanate groups and at least one hydrolyzable alkoxy group bonded to silicon; and optionally a polymer selected from the group consisting of polyethylene oxide, polyvinyl pyrrolidone, polyvinyl alcohol, polyethylene glycol, and polyacrylic acid.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 2 OF 32 USPATFULL

DUPLICATE 2

ACCESSION NUMBER:

2002:32527 USPATFULL

TITLE:

Use of relaxin treat diseases related to

vasoconstriction

INVENTOR(S):

Conrad, Kirk P., Cranberry Township, PA, UNITED STATES

Lewis, Martyn, Menlo park, CA, UNITED STATES Unemori, Elaine N., Oakland, CA, UNITED STATES Huang, Xinfan, Menlo Park, CA, UNITED STATES Tozzi, Carol A., Jackson, NJ, UNITED STATES

KIND DATE NUMBER -----------------PATENT INFORMATION: APPLICATION INFO.: US 2002019349 A1 20020214 US 2001-780752 A1 20010209 (9)

> NUMBER DATE

PRIORITY INFORMATION:

US 2000-181408P 20000209 (60) US 2000-200284P 20000428 (60) US 2000-242216P 20001020 (60)

DOCUMENT TYPE: FILE SEGMENT:

Utility APPLICATION

LEGAL REPRESENTATIVE: Paula A. Borden, BOZICEVIC, FIELD & FRANCIS LLP, 200

Middlefield Road, Suite 200, Menlo Park, CA, 94025

NUMBER OF CLAIMS: EXEMPLARY CLAIM:

27

NUMBER OF DRAWINGS:

15 Drawing Page(s)

LINE COUNT:

2559

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

The invention relates to methods of treating diseases related to vasodilation, generally comprising administering to an

individual an effective amount of a pharmaceutically active

relaxin. Relaxin functions to increase both

vasodilation and angiogenesis in males as well as females, and

is therefore useful in treating a wide variety of diseases relating to

vasoconstriction.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ANSWER 3 OF 32 USPATFULL

ACCESSION NUMBER:

2002:227663 USPATFULL

TITLE:

Uses for medical devices having a lubricious, nitric

oxide-releasing coating

INVENTOR(S):

Tedeschi, Eugene, Santa Rosa, CA, UNITED STATES

Shah, Chirag B., North Attleboro, MA, UNITED STATES

NUMBER KIND DATE -----US 2002122814 A1 20020905 US 2002-137236 A1 20020430 PATENT INFORMATION:

APPLICATION INFO.: RELATED APPLN. INFO.:

Continuation of Ser. No. US 2000-726856, filed on 30

Nov 2000, GRANTED, Pat. No. US 6379691

Continuation-in-part of Ser. No. US 1999-405024, filed

on 27 Sep 1999, GRANTED, Pat. No. US 6218016

Continuation-in-part of Ser. No. US 1998-163038, filed

on 29 Sep 1998, GRANTED, Pat. No. US 6299980

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: Christine Aceves, Medtronic AVE, 3576 Unocal Place,

Santa Rosa, CA, 95403

NUMBER OF CLAIMS: EXEMPLARY CLAIM: LINE COUNT:

1241

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

Methods are provided for delivering nitric oxide to the vascular tissue of a patient to inhibit or prevent restenosis or improve vascular function following various surgical procedures or associated with various NO-related conditions. The disclosed methods comprise contacting the vascular tissue of a patient with a medical device coated with a coating comprising nitric oxide associated with and releaseable from a polyurea network formed from the reaction on said medical device of a polyisocyanate; an amine donor and/or hydroxyl donor; an isocyanatosilane adduct having terminal isocyanate groups and at least one hydrolyzable alkoxy group bonded to silicon; and optionally a

polymer selected from the group consisting of polyethylene oxide, polyvinyl pyrrolidone, polyvinyl alcohol, polyethylene glycol, and polyacrylic acid.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ANSWER 4 OF 32 CAPLUS COPYRIGHT 2002 ACS L9 **DUPLICATE 3**

ACCESSION NUMBER:

2001:597816 CAPLUS

DOCUMENT NUMBER:

135:175377

TITLE:

Use of relaxin to treat diseases related to

vasoconstriction

INVENTOR (S):

Conrad, Kirk P.; Lewis, Martyn; Unemori, Elaine N.;

PATENT ASSIGNEE(S):

Huang, Xinfan; Tozzi, Carol A. Connetics Corp., USA; The University of Pittsburgh of the Commonwealth System of Higher Education; The University of Medicine and Dentistry of New Jersey -

Robert Wood Johnson Medical School

SOURCE:

PCT Int. Appl., 73 pp.

DOCUMENT TYPE:

CODEN: PIXXD2 Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT	NO.	KIND DATE	}	APPLI	CATION NO	DATE	
			- -				
WO 2001	058468	A1 2001	0816	WO 20	01-US4370	20010	209
₩:	AE, AG, A	L, AM, AT,	AU, AZ,	BA, BB,	BG, BR,	BY, BZ,	CA, CH, CN,
	CR, CU, C	Z, DE, DK,	DM, DZ,	EE, ES,	FI, GB,	GD, GE, G	GH, GM, HR,
							LR, LS, LT,
							PT, RO, RU,
							UZ, VN, YU,
	ZA, ZW, A	M, AZ, BY,	KG, KZ,	MD, RU,	TJ, TM		
RW:	GH, GM, K	E, LS, MW,	MZ, SD,	SL, SZ,	TZ, UG,	ZW, AT, 1	BE, CH, CY,
	DE, DK, E	S, FI, FR,	GB, GR,	IE, IT,	LU, MC,	NL, PT,	SE, TR, BF,
	BJ, CF, C	G, CI, CM,	GA, GN,	GW, ML,	MR, NE,	SN, TD,	I G
US 2002	019349	A1 2002	0214	US 20	01-780752	20010:	209
EP 1253	929	A1 2002	1106	EP 20	01-909098	20010:	209
R:	AT, BE, C	H, DE, DK,	ES, FR,	GB, GR,	IT, LI,	LU, NL,	SE, MC, PT,
	IE, SI, L'	r, LV, FI,	RO, MK,	CY, AL,	TR		
PRIORITY APP	LN. INFO.:			US 2000-	181408P	P 20000	209
				US 2000-	200284P	P 200004	428
				US 2000-	242216P	P 200010	020
				WO 2001-	US4370	W 200102	209
AR The inv	ention rel	ates to mo	thoda of	++			3 4 -

The invention relates to methods of treating diseases related to AB vasoconstriction, generally comprising administering to an individual an effective amt. of a pharmaceutically active relaxin. Relaxin functions to increase both vasodilation and

angiogenesis in males as well as females, and is therefore useful in treating a wide variety of diseases relating to vasoconstriction.

REFERENCE COUNT:

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

1.9 ANSWER 5 OF 32 USPATFULL **DUPLICATE 4**

ACCESSION NUMBER:

1999:110286 USPATFULL

TITLE:

Method of using relaxin as therapeutic or

preventing agent

INVENTOR (S):

Bigazzi, Mario, Via del Palmerino No.11, Florence,

Italy 50137

	NUMBER	KIND	DATE	
 -				
PATENT INFORMATION: US	5952296		19990914	
WO	9503822		19950209	
APPLICATION INFO.: US	1995-403878		19950323	(8)
WO	1994-IT124		19940726	

NUMBER DATE

PRIORITY INFORMATION: IT 1993-FI143 19930727 IT 1994-FI36 19940219

IT 1994-FI39 19940225

DOCUMENT TYPE: Utility FILE SEGMENT: Granted

PRIMARY EXAMINER: Tsang, Cecilia J.
ASSISTANT EXAMINER: Delacroix-Muirheid, C.
LEGAL REPRESENTATIVE: McGlew and Tuttle, P.C.

NUMBER OF CLAIMS: 37 EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 15 Drawing Figure(s); 5 Drawing Page(s)

LINE COUNT: 750

AB Methods of using relaxin (RLX), a peptide hormone of the insulin family, which has been found to produce effects on the walls of blood vessels, on blood clotting and on blood lipids and electrolytes, per se, and through the stimulation of the synthesis and release of the two powerful substances: nitric oxide (NO) and atrial natriuretic peptide (ANP), are contemplated whereby RLX is administered to a patient for increasing blood flow, producing dilation of the arteries, influencing blood clotting and fibrinolysis, reducing blood lipids, inducing reduction of blood osmolarity and sodium concentration, and through NO for inhibiting release of histamine from mast cells. RLX is accordingly used as a therapeutic agent in methods for treating arteriosclerosis and vascular diseases, ischemia and thrombosis, hypertension and pregnancy's gestosis, and other diseases, or allergic and inflammatory disorders as dysfunctions in fluid and electrolyte balance.

L9 ANSWER 6 OF 32 USPATFULL

ACCESSION NUMBER: 1999:132779 USPATFULL

TITLE: Peptides having potassium channel opener activity
INVENTOR(S): Sinackevich, Nickolai V., St. Petersburg, Russian

Federation

Rakhilov, Alexi M., St. Petersburg, Russian Federation

Maslennikov, Sergei V., St. Petersburg, Russian

Federation

Green, Lawrence R., Tacoma, WA, United States Cytran, Inc., Kirkland, WA, United States (U.S.

corporation)

NUMBER KIND DATE

PATENT INFORMATION: US 5972894 19991026
APPLICATION INFO.: US 1997-908328 19970807 (8)

DOCUMENT TYPE: Utility FILE SEGMENT: Granted

PRIMARY EXAMINER: Criares, Theodore J.

LEGAL REPRESENTATIVE: Townsend & Townsend and Crew LLP

NUMBER OF CLAIMS: 67 EXEMPLARY CLAIM: 1 LINE COUNT: 3605

L9

PATENT ASSIGNEE(S):

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention concerns methods for prophylactic and therapeutic treatment of diseases responsive to the opening of potassium channels, peptides having potassium channel opener activities, and pharmaceutical compositions and kits comprising such peptides.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: AAD14414 DNA **DGENE**

Treating pulmonary or renal hypertension and an TITLE:

ischemic condition, increasing vasodilation

and renal function, promoting wound healing and increasing production of angiogenic cytokine, comprises administering

relaxin -

Conrad K P; Lewis M; Unemori E N; Huang X; Tozzi C A INVENTOR:

PATENT ASSIGNEE: (CONN-N) CONNETICS CORP.

UNIV PITTSBURGH. (UYPI-N)

UNIV NEW JERSEY MEDICINE & DENTISTRY. (UYNE-N)

WO 2001058468 A1 20010816 73p PATENT INFO:

APPLICATION INFO: WO 2001-US4370 20010209 US 2000-181408 20000209 PRIORITY INFO:

> 20000428 US 2000-200284 US 2000-242216 20001020

DOCUMENT TYPE: Patent LANGUAGE: English

OTHER SOURCE: 2001-514619 [56]

AAD14414 DNA DGENE ΔN

The invention relates to methods of treating diseases related to AR

vasodilation by administering pharmaceutically active

relaxin. Relaxin functions to increase both

vasodilation and angiogenesis in males as well as females and is therefore useful in treating a wide variety of diseases relating to vasoconstriction. The method is used for treating renal or pulmonary hypertension, treating ischaemic conditions such as ischaemic wound, stroke or ischaemic cardiac conditional, for increasing production of an angiogenic cytokine such as basic fibroblast growth factor (bFGF) or a vascular endothelial growth factor, increasing vasodilation , increasing renal function by increasing glomerular filtration rate, promoting wound healing, increasing nitric oxide production in an endothelial cell of a blood vessel endothelium and for increasing endothelin type B receptor activation in an endothelial cell in a blood

vessel endothelium. Relaxin is useful for treating diseases related to vasoconstriction such as angiotensin-II-mediated vasoconstriction, endothelin-mediated vasoconstriction and for increasing angiogenesis and to promote neovascularisation in both males and females. It also promotes renal vasodilation and hyperfiltration. The

gene encoding relaxin is used in gene therapy. The present sequence is an alpha sense RT (reverse transcription) - PCR primer used to

ANSWER 8 OF 32 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAD14413 DNA **DGENE**

amplify human GAPDH.

TITLE: Treating pulmonary or renal hypertension and an

ischemic condition, increasing vasodilation

and renal function, promoting wound healing and increasing production of angiogenic cytokine, comprises administering

relaxin -

INVENTOR: Conrad K P; Lewis M; Unemori E N; Huang X; Tozzi C A

PATENT ASSIGNEE: (CONN-N) CONNETICS CORP.

UNIV PITTSBURGH. (UYPI-N)

UNIV NEW JERSEY MEDICINE & DENTISTRY. (UYNE-N)

PATENT INFO: WO 2001058468 A1 20010816 73p

APPLICATION INFO: WO 2001-US4370 20010209 PRIORITY INFO: US 2000-181408 20000209 US 2000-200284

20000428 US 2000-242216 20001020

DOCUMENT TYPE: Patent LANGUAGE: English

OTHER SOURCE: 2001-514619 [56] AN DGENE

The invention relates to methods of treating diseases related to AB vasodilation by administering pharmaceutically active

relaxin. Relaxin functions to increase both

vasodilation and angiogenesis in males as well as females and is

therefore useful in treating a wide variety of diseases relating to vasoconstriction. The method is used for treating renal or pulmonary hypertension, treating ischaemic conditions such as ischaemic wound, stroke or ischaemic cardiac conditional, for increasing production of an angiogenic cytokine such as basic fibroblast growth factor (bFGF) or a vascular endothelial growth factor, increasing vasodilation , increasing renal function by increasing glomerular filtration rate, promoting wound healing, increasing nitric oxide production in an endothelial cell of a blood vessel endothelium and for increasing endothelin type B receptor activation in an endothelial cell in a blood vessel endothelium. Relaxin is useful for treating diseases related to vasoconstriction such as angiotensin-II-mediated vasoconstriction, endothelin-mediated vasoconstriction and for increasing angiogenesis and to promote neovascularisation in both males and females. It also promotes renal vasodilation and hyperfiltration. The gene encoding relaxin is used in gene therapy. The present sequence is a sense RT (reverse transcription)-PCR primer used to amplify human GAPDH.

ANSWER 9 OF 32 DGENE (C) 2002 THOMSON DERWENT 1.9

ACCESSION NUMBER: AAD14412 DNA DGENE

TITLE: Treating pulmonary or renal hypertension and an

ischemic condition, increasing vasodilation

and renal function, promoting wound healing and increasing production of angiogenic cytokine, comprises administering

relaxin -

INVENTOR: Conrad K P; Lewis M; Unemori E N; Huang X; Tozzi C A

PATENT ASSIGNEE: (CONN-N) CONNETICS CORP.

(UYPI-N) UNIV PITTSBURGH.

UNIV NEW JERSEY MEDICINE & DENTISTRY. (UYNE-N)

WO 2001058468 A1 20010816 PATENT INFO: 73p

APPLICATION INFO: WO 2001-US4370 20010209 PRIORITY INFO: US 2000-181408 20000209 US 2000-200284 20000428

US 2000-242216 20001020

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2001-514619 [56]

AAD14412 DNA ANDGENE AB The invention relates to methods of treating diseases related to vasodilation by administering pharmaceutically active relaxin. Relaxin functions to increase both vasodilation and angiogenesis in males as well as females and is therefore useful in treating a wide variety of diseases relating to vasoconstriction. The method is used for treating renal or pulmonary hypertension, treating ischaemic conditions such as ischaemic wound, stroke or ischaemic cardiac conditional, for increasing production of an angiogenic cytokine such as basic fibroblast growth factor (bFGF) or a vascular endothelial growth factor, increasing vasodilation , increasing renal function by increasing glomerular filtration rate, promoting wound healing, increasing nitric oxide production in an endothelial cell of a blood vessel endothelium and for increasing endothelin type B receptor activation in an endothelial cell in a blood vessel endothelium. Relaxin is useful for treating diseases related to vasoconstriction such as angiotensin-II-mediated vasoconstriction, endothelin-mediated vasoconstriction and for increasing angiogenesis and to promote neovascularisation in both males and females. It also promotes renal vasodilation and hyperfiltration. The gene encoding relaxin is used in gene therapy. The present sequence is a sense probe used in the RT (reverse transcription)-PCR

ANSWER 10 OF 32 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAD14411 DNA DGENE

analysis of human GAPDH.

TITLE: Treating pulmonary or renal hypertension and an ischemic condition, increasing vasodilation

and renal function, promoting wound healing and increasing production of angiogenic cytokine, comprises administering

relaxin -

INVENTOR: Conrad K P; Lewis M; Unemori E N; Huang X; Tozzi C A

PATENT ASSIGNEE: (CONN-N) CONNETICS CORP.

(UYPI-N) UNIV PITTSBURGH.

(UYNE-N) UNIV NEW JERSEY MEDICINE & DENTISTRY.

PATENT INFO: WO 2001058468 A1 20010816 73p

APPLICATION INFO: WO 2001-US4370 20010209 PRIORITY INFO: US 2000-181408 20000209 US 2000-200284 20000428 US 2000-242216 20001020

DOCUMENT TYPE: Patent LANGUAGE: English

OTHER SOURCE: 2001-514619 [56] AN AAD14411 DNA DGENE

AB The invention relates to methods of treating diseases related to **vasodilation** by administering pharmaceutically active

relaxin. Relaxin functions to increase both vasodilation and angiogenesis in males as well as females and is therefore useful in treating a wide variety of diseases relating to vasoconstriction. The method is used for treating renal or pulmonary hypertension, treating ischaemic conditions such as ischaemic wound, stroke or ischaemic cardiac conditional, for increasing production of an angiogenic cytokine such as basic fibroblast growth factor (bFGF) or a vascular endothelial growth factor, increasing vasodilation , increasing renal function by increasing glomerular filtration rate, promoting wound healing, increasing nitric oxide production in an endothelial cell of a blood vessel endothelium and for increasing endothelin type B receptor activation in an endothelial cell in a blood vessel endothelium. Relaxin is useful for treating diseases related to vasoconstriction such as angiotensin-II-mediated vasoconstriction, endothelin-mediated vasoconstriction and for increasing angiogenesis and to promote neovascularisation in both males and females. It also promotes renal vasodilation and hyperfiltration. The gene encoding relaxin is used in gene therapy. The present sequence is an alpha sense RT (reverse transcription) - PCR primer used to

L9 ANSWER 11 OF 32 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAD14410 DNA DGENE

amplify human HGF.

TITLE: Treating pulmonary or renal hypertension and an

ischemic condition, increasing vasodilation

and renal function, promoting wound healing and increasing production of angiogenic cytokine, comprises administering

relaxin -

INVENTOR: Conrad K P; Lewis M; Unemori E N; Huang X; Tozzi C A

PATENT ASSIGNEE: (CONN-N) CONNETICS CORP.

(UYPI-N) UNIV PITTSBURGH.

(UYNE-N) UNIV NEW JERSEY MEDICINE & DENTISTRY.

PATENT INFO: WO 2001058468 Al 20010816 73p

APPLICATION INFO: WO 2001-US4370 20010209 PRIORITY INFO: US 2000-181408 20000209 US 2000-200284 20000428

US 2000-242216 20001020

DOCUMENT TYPE: Patent LANGUAGE: English

OTHER SOURCE: 2001-514619 [56]
AN AAD14410 DNA DGENE

The invention relates to methods of treating diseases related to vasodilation by administering pharmaceutically active relaxin. Relaxin functions to increase both vasodilation and angiogenesis in males as well as females and is therefore useful in treating a wide variety of diseases relating to

vasoconstriction. The method is used for treating renal or pulmonary hypertension, treating ischaemic conditions such as ischaemic

wound, stroke or ischaemic cardiac conditional, for increasing production of an angiogenic cytokine such as basic fibroblast growth factor (bFGF) or a vascular endothelial growth factor, increasing vasodilation , increasing renal function by increasing glomerular filtration rate, promoting wound healing, increasing nitric oxide production in an endothelial cell of a blood vessel endothelium and for increasing endothelin type B receptor activation in an endothelial cell in a blood vessel endothelium. Relaxin is useful for treating diseases related to vasoconstriction such as angiotensin-II-mediated vasoconstriction, endothelin-mediated vasoconstriction and for increasing angiogenesis and to promote neovascularisation in both males and females. It also promotes renal vasodilation and hyperfiltration. The gene encoding relaxin is used in gene therapy. The present sequence is a sense RT (reverse transcription)-PCR primer used to amplify human HGF.

ANSWER 12 OF 32 DGENE (C) 2002 THOMSON DERWENT L9

ACCESSION NUMBER: AAD14409 DNA DGENE

Treating pulmonary or renal hypertension and an TITLE:

ischemic condition, increasing vasodilation

and renal function, promoting wound healing and increasing production of angiogenic cytokine, comprises administering

relaxin -

Conrad K P; Lewis M; Unemori E N; Huang X; Tozzi C A INVENTOR:

PATENT ASSIGNEE: (CONN-N) CONNETICS CORP.

> (UYPI-N) UNIV PITTSBURGH.

UNIV NEW JERSEY MEDICINE & DENTISTRY. (UYNE-N)

PATENT INFO: WO 2001058468 A1 20010816 73p

APPLICATION INFO: WO 2001-US4370 20010209 US 2000-181408 20000209 PRIORITY INFO: US 2000-200284 20000428

US 2000-242216 20001020

DOCUMENT TYPE: Patent LANGUAGE: English

OTHER SOURCE: 2001-514619 [56] ΑN AAD14409 DNA **DGENE**

AB The invention relates to methods of treating diseases related to vasodilation by administering pharmaceutically active relaxin. Relaxin functions to increase both

vasodilation and angiogenesis in males as well as females and is therefore useful in treating a wide variety of diseases relating to vasoconstriction. The method is used for treating renal or pulmonary hypertension, treating ischaemic conditions such as ischaemic wound, stroke or ischaemic cardiac conditional, for increasing production of an angiogenic cytokine such as basic fibroblast growth factor (bFGF) or a vascular endothelial growth factor, increasing vasodilation , increasing renal function by increasing glomerular filtration rate, promoting wound healing, increasing nitric oxide production in an endothelial cell of a blood vessel endothelium and for increasing endothelin type B receptor activation in an endothelial cell in a blood vessel endothelium. Relaxin is useful for treating diseases related to vasoconstriction such as angiotensin-II-mediated vasoconstriction, endothelin-mediated vasoconstriction and for increasing angiogenesis and to promote neovascularisation in both males and females. It also promotes renal vasodilation and hyperfiltration. The gene encoding relaxin is used in gene therapy. The present sequence is an alpha sense RT (reverse transcription) - PCR primer used to amplify human bFGF.

ANSWER 13 OF 32 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAD14408 DNA DGENE

TITLE: Treating pulmonary or renal hypertension and an ischemic condition, increasing vasodilation

> and renal function, promoting wound healing and increasing production of angiogenic cytokine, comprises administering relaxin -

Conrad K P; Lewis M; Unemori E N; Huang X; Tozzi C A INVENTOR:

(CONN-N) CONNETICS CORP. PATENT ASSIGNEE:

UNIV PITTSBURGH. (UYPI-N)

UNIV NEW JERSEY MEDICINE & DENTISTRY. (UYNE-N)

WO 2001058468 A1 20010816 73p PATENT INFO:

20010209 APPLICATION INFO: WO 2001-US4370 PRIORITY INFO: US 2000-181408 20000209

> US 2000-200284 20000428 US 2000-242216 20001020

DOCUMENT TYPE: Patent English LANGUAGE:

2001-514619 [56] OTHER SOURCE:

DGENE AAD14408 DNA AN The invention relates to methods of treating diseases related to AB

vasodilation by administering pharmaceutically active

relaxin. Relaxin functions to increase both

vasodilation and angiogenesis in males as well as females and is therefore useful in treating a wide variety of diseases relating to vasoconstriction. The method is used for treating renal or pulmonary hypertension, treating ischaemic conditions such as ischaemic wound, stroke or ischaemic cardiac conditional, for increasing production of an angiogenic cytokine such as basic fibroblast growth factor (bFGF) or a vascular endothelial growth factor, increasing vasodilation , increasing renal function by increasing glomerular filtration rate, promoting wound healing, increasing nitric oxide production in an endothelial cell of a blood vessel endothelium and for increasing endothelin type B receptor activation in an endothelial cell in a blood vessel endothelium. Relaxin is useful for treating diseases related to vasoconstriction such as angiotensin-II-mediated vasoconstriction, endothelin-mediated vasoconstriction and for increasing angiogenesis and to promote neovascularisation in both males and females. It also promotes renal vasodilation and hyperfiltration. The

sequence is a sense RT (reverse transcription)-PCR primer used to amplify human bFGF.

ANSWER 14 OF 32 DGENE (C) 2002 THOMSON DERWENT 1.9

ACCESSION NUMBER: AAD14407 DNA **DGENE**

TITLE: Treating pulmonary or renal hypertension and an

ischemic condition, increasing vasodilation

and renal function, promoting wound healing and increasing production of angiogenic cytokine, comprises administering

relaxin -

Conrad K P; Lewis M; Unemori E N; Huang X; Tozzi C A INVENTOR:

gene encoding relaxin is used in gene therapy. The present

PATENT ASSIGNEE: (CONN-N) CONNETICS CORP.

(UYPI-N) UNIV PITTSBURGH.

UNIV NEW JERSEY MEDICINE & DENTISTRY. (UYNE-N)

WO 2001058468 A1 20010816 73p PATENT INFO:

APPLICATION INFO: WO 2001-US4370 20010209 PRIORITY INFO: US 2000-181408 20000209

> US 2000-200284 20000428 US 2000-242216 20001020

DOCUMENT TYPE: Patent LANGUAGE: English

2001-514619 [56] OTHER SOURCE: AAD14407 DNA ΑN DGENE

The invention relates to methods of treating diseases related to AB

vasodilation by administering pharmaceutically active

relaxin. Relaxin functions to increase both

vasodilation and angiogenesis in males as well as females and is therefore useful in treating a wide variety of diseases relating to vasoconstriction. The method is used for treating renal or pulmonary hypertension, treating ischaemic conditions such as ischaemic wound, stroke or ischaemic cardiac conditional, for increasing production of an angiogenic cytokine such as basic fibroblast growth factor (bFGF)

or a vascular endothelial growth factor, increasing vasodilation

, increasing renal function by increasing glomerular filtration rate, promoting wound healing, increasing nitric oxide production in an endothelial cell of a blood vessel endothelium and for increasing endothelin type B receptor activation in an endothelial cell in a blood vessel endothelium. Relaxin is useful for treating diseases related to vasoconstriction such as angiotensin-II-mediated vasoconstriction, endothelin-mediated vasoconstriction and for increasing angiogenesis and to promote neovascularisation in both males and females. It also promotes renal vasodilation and hyperfiltration. The gene encoding relaxin is used in gene therapy. The present sequence is a sense probe used in the RT (reverse transcription)-PCR analysis of human bFGF.

L9 ANSWER 15 OF 32 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAD14406 DNA DGENE

TITLE: Treating pulmonary or renal hypertension and an

ischemic condition, increasing vasodilation

and renal function, promoting wound healing and increasing production of angiogenic cytokine, comprises administering

relaxin -

INVENTOR: Conrad K P; Lewis M; Unemori E N; Huang X; Tozzi C A

PATENT ASSIGNEE: (CONN-N) CONNETICS CORP.

(UYPI-N) UNIV PITTSBURGH.

(UYNE-N) UNIV NEW JERSEY MEDICINE & DENTISTRY.

PATENT INFO: WO 2001058468 A1 20010816 73p

APPLICATION INFO: WO 2001-US4370 20010209 PRIORITY INFO: US 2000-181408 20000209 US 2000-200284 20000428 US 2000-242216 20001020

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2001-514619 [56]
AN AAD14406 DNA DGENE

AB The invention relates to methods of treating diseases related to **vasodilation** by administering pharmaceutically active

relaxin. Relaxin functions to increase both

vasodilation and angiogenesis in males as well as females and is therefore useful in treating a wide variety of diseases relating to vasoconstriction. The method is used for treating renal or pulmonary hypertension, treating ischaemic conditions such as ischaemic wound, stroke or ischaemic cardiac conditional, for increasing production of an angiogenic cytokine such as basic fibroblast growth factor (bFGF) or a vascular endothelial growth factor, increasing vasodilation , increasing renal function by increasing glomerular filtration rate, promoting wound healing, increasing nitric oxide production in an endothelial cell of a blood vessel endothelium and for increasing endothelin type B receptor activation in an endothelial cell in a blood vessel endothelium. Relaxin is useful for treating diseases related to vasoconstriction such as angiotensin-II-mediated vasoconstriction, endothelin-mediated vasoconstriction and for increasing angiogenesis and to promote neovascularisation in both males and females. It also promotes renal vasodilation and hyperfiltration. The gene encoding relaxin is used in gene therapy. The present sequence is an alpha sense RT (reverse transcription) - PCR primer used to amplify human vascular endothelial cell growth factor (VEGF) 121.

L9 ANSWER 16 OF 32 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAD14405 DNA DGENE

TITLE: Treating pulmonary or renal hypertension and an

ischemic condition, increasing vasodilation

and renal function, promoting wound healing and increasing production of angiogenic cytokine, comprises administering

relaxin -

INVENTOR: Conrad K P; Lewis M; Unemori E N; Huang X; Tozzi C A

PATENT ASSIGNEE: (CONN-N) CONNETICS CORP.

(UYPI-N) UNIV PITTSBURGH.

UNIV NEW JERSEY MEDICINE & DENTISTRY. (UYNE-N)

WO 2001058468 A1 20010816 PATENT INFO: 20010209

APPLICATION INFO: WO 2001-US4370 US 2000-181408 20000209 PRIORITY INFO:

US 2000-200284 20000428 US 2000-242216 20001020

DOCUMENT TYPE: Patent English LANGUAGE:

2001-514619 [56] OTHER SOURCE: AAD14405 DNA DGENE AN

The invention relates to methods of treating diseases related to AB

vasodilation by administering pharmaceutically active

relaxin. Relaxin functions to increase both

vasodilation and angiogenesis in males as well as females and is therefore useful in treating a wide variety of diseases relating to vasoconstriction. The method is used for treating renal or pulmonary hypertension, treating ischaemic conditions such as ischaemic wound, stroke or ischaemic cardiac conditional, for increasing production of an angiogenic cytokine such as basic fibroblast growth factor (bFGF) or a vascular endothelial growth factor, increasing vasodilation

73p

, increasing renal function by increasing glomerular filtration rate, promoting wound healing, increasing nitric oxide production in an endothelial cell of a blood vessel endothelium and for increasing endothelin type B receptor activation in an endothelial cell in a blood vessel endothelium. Relaxin is useful for treating diseases related to vasoconstriction such as angiotensin-II-mediated vasoconstriction, endothelin-mediated vasoconstriction and for increasing angiogenesis and to promote neovascularisation in both males and females. It also promotes renal vasodilation and hyperfiltration. The gene encoding relaxin is used in gene therapy. The present sequence is a sense RT (reverse transcription)-PCR primer used to amplify human vascular endothelial cell growth factor (VEGF) 121.

ANSWER 17 OF 32 DGENE (C) 2002 THOMSON DERWENT L9.

ACCESSION NUMBER: AAD14404 DNA **DGENE**

Treating pulmonary or renal hypertension and an TITLE:

ischemic condition, increasing vasodilation

and renal function, promoting wound healing and increasing production of angiogenic cytokine, comprises administering

relaxin -

INVENTOR: Conrad K P; Lewis M; Unemori E N; Huang X; Tozzi C A

PATENT ASSIGNEE: (CONN-N) CONNETICS CORP.

> (UYPI-N) UNIV PITTSBURGH.

UNIV NEW JERSEY MEDICINE & DENTISTRY. (UYNE-N)

WO 2001058468 A1 20010816 PATENT INFO: 73p

APPLICATION INFO: WO 2001-US4370 20010209 US 2000-181408 20000209 PRIORITY INFO: US 2000-200284 20000428

US 2000-242216 20001020

DOCUMENT TYPE: Patent LANGUAGE: English

OTHER SOURCE: 2001-514619 [56] AAD14404 DNA ΔN DGENE

AR The invention relates to methods of treating diseases related to

vasodilation by administering pharmaceutically active

relaxin. Relaxin functions to increase both

vasodilation and angiogenesis in males as well as females and is therefore useful in treating a wide variety of diseases relating to vasoconstriction. The method is used for treating renal or pulmonary hypertension, treating ischaemic conditions such as ischaemic wound, stroke or ischaemic cardiac conditional, for increasing production of an angiogenic cytokine such as basic fibroblast growth factor (bFGF) or a vascular endothelial growth factor, increasing vasodilation , increasing renal function by increasing glomerular filtration rate, promoting wound healing, increasing nitric oxide production in an

endothelial cell of a blood vessel endothelium and for increasing

endothelin type B receptor activation in an endothelial cell in a blood vessel endothelium. Relaxin is useful for treating diseases related to vasoconstriction such as angiotensin-II-mediated vasoconstriction, endothelin-mediated vasoconstriction and for increasing angiogenesis and to promote neovascularisation in both males and females. It also promotes renal vasodilation and hyperfiltration. The gene encoding relaxin is used in gene therapy. The present sequence is a sense probe used in the RT (reverse transcription)-PCR analysis of human rat vascular endothelial cell growth factor (VEGF) 121.

L9 ANSWER 18 OF 32 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAD14403 DNA DGENE

TITLE: Treating pulmonary or renal hypertension and an

ischemic condition, increasing vasodilation

and renal function, promoting wound healing and increasing production of angiogenic cytokine, comprises administering

relaxin -

INVENTOR: Conrad K P; Lewis M; Unemori E N; Huang X; Tozzi C A

PATENT ASSIGNEE: (CONN-N) CONNETICS CORP.

(UYPI-N) UNIV PITTSBURGH.

(UYNE-N) UNIV NEW JERSEY MEDICINE & DENTISTRY.

PATENT INFO: WO 2001058468 A1 20010816 73p

APPLICATION INFO: WO 2001-US4370 20010209 PRIORITY INFO: US 2000-181408 20000209

US 2000-200284 20000428 US 2000-242216 20001020

DOCUMENT TYPE: Patent LANGUAGE: English

OTHER SOURCE: 2001-514619 [56] AN AAD14403 DNA DGENE

AB The invention relates to methods of treating diseases related to vasodilation by administering pharmaceutically active

relaxin. Relaxin functions to increase both

vasodilation and angiogenesis in males as well as females and is therefore useful in treating a wide variety of diseases relating to vasoconstriction. The method is used for treating renal or pulmonary hypertension, treating ischaemic conditions such as ischaemic wound, stroke or ischaemic cardiac conditional, for increasing production of an angiogenic cytokine such as basic fibroblast growth factor (bFGF)

or a vascular endothelial growth factor, increasing vasodilation, increasing renal function by increasing glomerular filtration rate, promoting wound healing, increasing nitric oxide production in an endothelial cell of a blood vessel endothelium and for increasing endothelin type B receptor activation in an endothelial cell in a blood vessel endothelium. Relaxin is useful for treating diseases related to vasoconstriction such as angiotensin-II-mediated vasoconstriction, endothelin-mediated vasoconstriction and for increasing angiogenesis and to promote neovascularisation in both males and females. It also promotes renal vasodilation and hyperfiltration. The gene encoding relaxin is used in gene therapy. The present

sequence is an alpha sense RT (reverse transcription)-PCR primer used to amplify human vascular endothelial cell growth factor (VEGF) 165.

L9 ANSWER 19 OF 32 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAD14402 DNA DGENE

TITLE: Treating pulmonary or renal hypertension and an

ischemic condition, increasing vasodilation

and renal function, promoting wound healing and increasing production of angiogenic cytokine, comprises administering

relaxin -

INVENTOR: Conrad K P; Lewis M; Unemori E N; Huang X; Tozzi C A

PATENT ASSIGNEE: (CONN-N) CONNETICS CORP.

(UYPI-N) UNIV PITTSBURGH.

(UYNE-N) UNIV NEW JERSEY MEDICINE & DENTISTRY.

PATENT INFO: WO 2001058468 A1 20010816 73p
APPLICATION INFO: WO 2001-US4370 20010209

PRIORITY INFO: US 2000-181408 20000209

> US 2000-200284 20000428 US 2000-242216 20001020

DOCUMENT TYPE:

Patent

LANGUAGE:

English

OTHER SOURCE:

2001-514619 [56]

AAD14402 DNA AN

DGENE

The invention relates to methods of treating diseases related to AB

vasodilation by administering pharmaceutically active

relaxin. Relaxin functions to increase both

vasodilation and angiogenesis in males as well as females and is therefore useful in treating a wide variety of diseases relating to vasoconstriction. The method is used for treating renal or pulmonary hypertension, treating ischaemic conditions such as ischaemic wound, stroke or ischaemic cardiac conditional, for increasing production of an angiogenic cytokine such as basic fibroblast growth factor (bFGF) or a vascular endothelial growth factor, increasing vasodilation , increasing renal function by increasing glomerular filtration rate, promoting wound healing, increasing nitric oxide production in an endothelial cell of a blood vessel endothelium and for increasing endothelin type B receptor activation in an endothelial cell in a blood vessel endothelium. Relaxin is useful for treating diseases related to vasoconstriction such as angiotensin-II-mediated vasoconstriction, endothelin-mediated vasoconstriction and for increasing angiogenesis and to promote neovascularisation in both males and females. It also promotes renal vasodilation and hyperfiltration. The gene encoding relaxin is used in gene therapy. The present

ANSWER 20 OF 32 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAD14401 DNA

DGENE

human vascular endothelial cell growth factor (VEGF) 165.

TITLE:

Treating pulmonary or renal hypertension and an

sequence is a sense RT (reverse transcription) - PCR primer used to amplify

ischemic condition, increasing vasodilation

and renal function, promoting wound healing and increasing production of angiogenic cytokine, comprises administering

73p

relaxin -

Conrad K P; Lewis M; Unemori E N; Huang X; Tozzi C A INVENTOR:

PATENT ASSIGNEE: (CONN-N) CONNETICS CORP.

UNIV PITTSBURGH. (UYPI-N)

UNIV NEW JERSEY MEDICINE & DENTISTRY. (UYNE-N)

PATENT INFO: WO 2001058468 A1 20010816

APPLICATION INFO: WO 2001-US4370 20010209 PRIORITY INFO: US 2000-181408 20000209

US 2000-200284 20000428

US 2000-242216 20001020

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2001-514619 [56]

ANAAD14401 DNA DGENE

AB The invention relates to methods of treating diseases related to vasodilation by administering pharmaceutically active

relaxin. Relaxin functions to increase both

vasodilation and angiogenesis in males as well as females and is therefore useful in treating a wide variety of diseases relating to vasoconstriction. The method is used for treating renal or pulmonary hypertension, treating ischaemic conditions such as ischaemic wound, stroke or ischaemic cardiac conditional, for increasing production of an angiogenic cytokine such as basic fibroblast growth factor (bFGF) or a vascular endothelial growth factor, increasing vasodilation , increasing renal function by increasing glomerular filtration rate,

promoting wound healing, increasing nitric oxide production in an endothelial cell of a blood vessel endothelium and for increasing endothelin type B receptor activation in an endothelial cell in a blood

vessel endothelium. Relaxin is useful for treating diseases related to vasoconstriction such as angiotensin-II-mediated vasoconstriction, endothelin-mediated vasoconstriction and for increasing angiogenesis and to promote neovascularisation in both males and females. It also promotes renal **vasodilation** and hyperfiltration. The gene encoding **relaxin** is used in gene therapy. The present sequence is a sense probe used in the RT (reverse transcription)-PCR analysis of human rat vascular endothelial cell growth factor (VEGF) 165.

L9 ANSWER 21 OF 32 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAD14400 DNA DGENE

TITLE: Treating pulmonary or renal hypertension and an

ischemic condition, increasing vasodilation

and renal function, promoting wound healing and increasing production of angiogenic cytokine, comprises administering

relaxin -

INVENTOR: Conrad K P; Lewis M; Unemori E N; Huang X; Tozzi C A

PATENT ASSIGNEE: (CONN-N) CONNETICS CORP.

(UYPI-N) UNIV PITTSBURGH.

(UYNE-N) UNIV NEW JERSEY MEDICINE & DENTISTRY.

PATENT INFO: WO 2001058468 Al 20010816 73p

APPLICATION INFO: WO 2001-US4370 20010209 PRIORITY INFO: US 2000-181408 20000209 US 2000-200284 20000428

US 2000-242216 20001020

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2001-514619 [56] AN AAD14400 DNA DGENE

AB The invention relates to methods of treating diseases related to vasodilation by administering pharmaceutically active

relaxin. Relaxin functions to increase both

vasodilation and angiogenesis in males as well as females and is therefore useful in treating a wide variety of diseases relating to vasoconstriction. The method is used for treating renal or pulmonary hypertension, treating ischaemic conditions such as ischaemic wound, stroke or ischaemic cardiac conditional, for increasing production of an angiogenic cytokine such as basic fibroblast growth factor (bFGF) or a vascular endothelial growth factor, increasing vasodilation, increasing renal function by increasing glomerular filtration rate, promoting wound healing, increasing nitric oxide production in an endothelial cell of a blood vessel endothelium and for increasing endothelium. Relaxin is useful for treating diseases related to vasoconstriction such as angiotensin-II-mediated

related to vasoconstriction such as angiotensin-II-mediated vasoconstriction, endothelin-mediated vasoconstriction and for increasing angiogenesis and to promote neovascularisation in both males and females. It also promotes renal **vasodilation** and hyperfiltration. The gene encoding **relaxin** is used in gene therapy. The present sequence is an alpha sense RT (reverse transcription)-PCR primer used to

amplify rat GAPDH.

L9 ANSWER 22 OF 32 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAD14399 DNA DGENE

TITLE: Treating pulmonary or renal hypertension and an ischemic condition, increasing vasodilation

and renal function, promoting wound healing and increasing production of angiogenic cytokine, comprises administering

relaxin -

INVENTOR: Conrad K P; Lewis M; Unemori E N; Huang X; Tozzi C A

PATENT ASSIGNEE: (CONN-N) CONNETICS CORP.

(UYPI-N) UNIV PITTSBURGH.

(UYNE-N) UNIV NEW JERSEY MEDICINE & DENTISTRY.

PATENT INFO: WO 2001058468 A1 20010816 73p
APPLICATION INFO: WO 2001-US4370 20010209
PRIORITY INFO: US 2000-181408 20000209

US 2000-200284 20000428 US 2000-242216 20001020 DOCUMENT TYPE: Patent English LANGUAGE:

OTHER SOURCE: 2001-514619 [56] AN AAD14399 DNA DGENE AB

The invention relates to methods of treating diseases related to vasodilation by administering pharmaceutically active relaxin. Relaxin functions to increase both vasodilation and angiogenesis in males as well as females and is therefore useful in treating a wide variety of diseases relating to vasoconstriction. The method is used for treating renal or pulmonary hypertension, treating ischaemic conditions such as ischaemic wound, stroke or ischaemic cardiac conditional, for increasing production of an angiogenic cytokine such as basic fibroblast growth factor (bFGF) or a vascular endothelial growth factor, increasing vasodilation , increasing renal function by increasing glomerular filtration rate, promoting wound healing, increasing nitric oxide production in an endothelial cell of a blood vessel endothelium and for increasing endothelin type B receptor activation in an endothelial cell in a blood vessel endothelium. Relaxin is useful for treating diseases related to vasoconstriction such as angiotensin-II-mediated vasoconstriction, endothelin-mediated vasoconstriction and for increasing angiogenesis and to promote neovascularisation in both males and females. It also promotes renal vasodilation and hyperfiltration. The gene encoding relaxin is used in gene therapy. The present

ANSWER 23 OF 32 DGENE (C) 2002 THOMSON DERWENT L9

ACCESSION NUMBER: AAD14398 DNA DGENE

TITLE:

Treating pulmonary or renal hypertension and an

sequence is a sense RT (reverse transcription)-PCR primer used to amplify

ischemic condition, increasing vasodilation

and renal function, promoting wound healing and increasing production of angiogenic cytokine, comprises administering

relaxin -

Conrad K P; Lewis M; Unemori E N; Huang X; Tozzi C A INVENTOR:

PATENT ASSIGNEE: (CONN-N) CONNETICS CORP.

(UYPI-N) UNIV PITTSBURGH.

(UYNE-N) UNIV NEW JERSEY MEDICINE & DENTISTRY.

PATENT INFO: WO 2001058468 A1 20010816 73p

APPLICATION INFO: WO 2001-US4370 20010209 PRIORITY INFO: US 2000-181408 20000209 US 2000-200284 20000428

US 2000-242216 20001020

DOCUMENT TYPE: Patent

rat GAPDH.

LANGUAGE: English

2001-514619 [56] OTHER SOURCE: AAD14398 DNA AN **DGENE**

AB The invention relates to methods of treating diseases related to vasodilation by administering pharmaceutically active

relaxin. Relaxin functions to increase both vasodilation and angiogenesis in males as well as females and is therefore useful in treating a wide variety of diseases relating to vasoconstriction. The method is used for treating renal or pulmonary hypertension, treating ischaemic conditions such as ischaemic wound, stroke or ischaemic cardiac conditional, for increasing production of an angiogenic cytokine such as basic fibroblast growth factor (bFGF) or a vascular endothelial growth factor, increasing vasodilation , increasing renal function by increasing glomerular filtration rate, promoting wound healing, increasing nitric oxide production in an endothelial cell of a blood vessel endothelium and for increasing endothelin type B receptor activation in an endothelial cell in a blood vessel endothelium. Relaxin is useful for treating diseases related to vasoconstriction such as angiotensin-II-mediated vasoconstriction, endothelin-mediated vasoconstriction and for increasing angiogenesis and to promote neovascularisation in both males and females. It also promotes renal vasodilation and hyperfiltration. The

gene encoding relaxin is used in gene therapy. The present sequence is a sense probe used in the RT (reverse transcription)-PCR analysis of rat GAPDH.

L9 ANSWER 24 OF 32 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAD14397 DNA DGENE

TITLE: Treating pulmonary or renal hypertension and an

ischemic condition, increasing vasodilation

and renal function, promoting wound healing and increasing production of angiogenic cytokine, comprises administering

relaxin -

INVENTOR: Conrad K P; Lewis M; Unemori E N; Huang X; Tozzi C A

PATENT ASSIGNEE: (CONN-N) CONNETICS CORP.

(UYPI-N) UNIV PITTSBURGH.

(UYNE-N) UNIV NEW JERSEY MEDICINE & DENTISTRY.

PATENT INFO: WO 2001058468 A1 20010816 73p

APPLICATION INFO: WO 2001-US4370 20010209 PRIORITY INFO: US 2000-181408 20000209 US 2000-200284 20000428 US 2000-242216 20001020

DOCUMENT TYPE: Patent LANGUAGE: English

OTHER SOURCE: 2001-514619 [56]

AN AAD14397 DNA DGENE

AB The invention relates to methods of treating diseases related to

vasodilation by administering pharmaceutically active

relaxin. Relaxin functions to increase both

vasodilation and angiogenesis in males as well as females and is therefore useful in treating a wide variety of diseases relating to vasoconstriction. The method is used for treating renal or pulmonary hypertension, treating ischaemic conditions such as ischaemic wound, stroke or ischaemic cardiac conditional, for increasing production

of an angiogenic cytokine such as basic fibroblast growth factor (bFGF) or a vascular endothelial growth factor, increasing vasodilation, increasing renal function by increasing glomerular filtration rate, promoting wound healing, increasing nitric oxide production in an endothelial cell of a blood vessel endothelium and for increasing endothelin type B receptor activation in an endothelial cell in a blood vessel endothelium. Relaxin is useful for treating diseases

related to vasoconstriction such as angiotensin-II-mediated vasoconstriction, endothelin-mediated vasoconstriction and for increasing angiogenesis and to promote neovascularisation in both males and females. It also promotes renal **vasodilation** and hyperfiltration. The

gene encoding relaxin is used in gene therapy. The present sequence is an alpha sense RT (reverse transcription)-PCR primer used to amplify rat bFGF.

L9 ANSWER 25 OF 32 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAD14396 DNA DGENE

TITLE: Treating pulmonary or renal hypertension and an

ischemic condition, increasing vasodilation

and renal function, promoting wound healing and increasing production of angiogenic cytokine, comprises administering

relaxin -

INVENTOR: Conrad K P; Lewis M; Unemori E N; Huang X; Tozzi C A

PATENT ASSIGNEE: (CONN-N) CONNETICS CORP.

(UYPI-N) UNIV PITTSBURGH.

(UYNE-N) UNIV NEW JERSEY MEDICINE & DENTISTRY.

PATENT INFO: WO 2001058468 A1 20010816 73p

APPLICATION INFO: WO 2001-US4370 20010209 PRIORITY INFO: US 2000-181408 20000209

US 2000-200284 20000428 US 2000-242216 20001020

DOCUMENT TYPE: Patent LANGUAGE: English

OTHER SOURCE: 2001-514619 [56]

AAD14396 DNA **DGENE** AN

AΒ

The invention relates to methods of treating diseases related to vasodilation by administering pharmaceutically active relaxin. Relaxin functions to increase both vasodilation and angiogenesis in males as well as females and is therefore useful in treating a wide variety of diseases relating to vasoconstriction. The method is used for treating renal or pulmonary hypertension, treating ischaemic conditions such as ischaemic wound, stroke or ischaemic cardiac conditional, for increasing production of an angiogenic cytokine such as basic fibroblast growth factor (bFGF) or a vascular endothelial growth factor, increasing vasodilation increasing renal function by increasing glomerular filtration rate, promoting wound healing, increasing nitric oxide production in an endothelial cell of a blood vessel endothelium and for increasing endothelin type B receptor activation in an endothelial cell in a blood vessel endothelium. Relaxin is useful for treating diseases related to vasoconstriction such as angiotensin-II-mediated vasoconstriction, endothelin-mediated vasoconstriction and for increasing angiogenesis and to promote neovascularisation in both males and females. It also promotes renal vasodilation and hyperfiltration. The gene encoding relaxin is used in gene therapy. The present sequence is a sense RT (reverse transcription)-PCR primer used to amplify rat bFGF.

L9 ANSWER 26 OF 32 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAD14395 DNA **DGENE**

Treating pulmonary or renal hypertension and an TITLE:

ischemic condition, increasing vasodilation

and renal function, promoting wound healing and increasing production of angiogenic cytokine, comprises administering

relaxin -

INVENTOR: Conrad K P; Lewis M; Unemori E N; Huang X; Tozzi C A

PATENT ASSIGNEE: (CONN-N) CONNETICS CORP.

> (UYPI-N) UNIV PITTSBURGH.

UNIV NEW JERSEY MEDICINE & DENTISTRY. (UYNE-N)

PATENT INFO: WO 2001058468 A1 20010816 73p

APPLICATION INFO: WO 2001-US4370 20010209 US 2000-181408 PRIORITY INFO: 20000209 US 2000-200284 20000428

US 2000-242216 20001020

DOCUMENT TYPE: Patent LANGUAGE: English

OTHER SOURCE: 2001-514619 [56]

AAD14395 DNA DGENE AN

The invention relates to methods of treating diseases related to AB vasodilation by administering pharmaceutically active relaxin. Relaxin functions to increase both vasodilation and angiogenesis in males as well as females and is therefore useful in treating a wide variety of diseases relating to vasoconstriction. The method is used for treating renal or pulmonary

hypertension, treating ischaemic conditions such as ischaemic wound, stroke or ischaemic cardiac conditional, for increasing production of an angiogenic cytokine such as basic fibroblast growth factor (bFGF) or a vascular endothelial growth factor, increasing vasodilation , increasing renal function by increasing glomerular filtration rate, promoting wound healing, increasing nitric oxide production in an endothelial cell of a blood vessel endothelium and for increasing endothelin type B receptor activation in an endothelial cell in a blood vessel endothelium. Relaxin is useful for treating diseases related to vasoconstriction such as angiotensin-II-mediated

vasoconstriction, endothelin-mediated vasoconstriction and for increasing angiogenesis and to promote neovascularisation in both males and females. It also promotes renal vasodilation and hyperfiltration. The

gene encoding relaxin is used in gene therapy. The present sequence is a sense probe used in the RT (reverse transcription)-PCR analysis of rat bFGF.

L9 ANSWER 27 OF 32 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAD14394 DNA

TITLE:

AAD14394 DNA DGENE
Treating pulmonary or renal hypertension and an

ischemic condition, increasing vasodilation

and renal function, promoting wound healing and increasing production of angiogenic cytokine, comprises administering

relaxin -

INVENTOR: Conrad K P; Lewis M; Unemori E N; Huang X; Tozzi C A

PATENT ASSIGNEE: (CONN-N) CONNETICS CORP.

(UYPI-N) UNIV PITTSBURGH.

(UYNE-N) UNIV NEW JERSEY MEDICINE & DENTISTRY.

PATENT INFO: WO 2001058468 A1 20010816 73p

APPLICATION INFO: WO 2001-US4370 20010209 PRIORITY INFO: US 2000-181408 20000209

US 2000-200284 20000428 US 2000-242216 20001020

DOCUMENT TYPE: Patent LANGUAGE: English

OTHER SOURCE: 2001-514619 [56]
AN AAD14394 DNA DGENE

AB The invention relates to methods of treating diseases related to

vasodilation by administering pharmaceutically active

relaxin. Relaxin functions to increase both

vasodilation and angiogenesis in males as well as females and is therefore useful in treating a wide variety of diseases relating to vasoconstriction. The method is used for treating renal or pulmonary hypertension, treating ischaemic conditions such as ischaemic

wound, stroke or ischaemic cardiac conditional, for increasing production of an angiogenic cytokine such as basic fibroblast growth factor (bFGF) or a vascular endothelial growth factor, increasing vasodilation, increasing renal function by increasing glomerular filtration rate,

promoting wound healing, increasing nitric oxide production in an endothelial cell of a blood vessel endothelium and for increasing endothelin type B receptor activation in an endothelial cell in a blood vessel endothelium. Relaxin is useful for treating diseases related to vasoconstriction such as angiotensin-II-mediated

vasoconstriction, endothelin-mediated vasoconstriction and for increasing angiogenesis and to promote neovascularisation in both males and females. It also promotes renal **vasodilation** and hyperfiltration. The

gene encoding **relaxin** is used in gene therapy. The present sequence is an alpha sense RT (reverse transcription)-PCR primer used to

amplify rat vascular endothelial cell growth factor (VEGF) 120.

L9 ANSWER 28 OF 32 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAD14393 DNA DGENE

TITLE: Treating pulmonary or renal hypertension and an

ischemic condition, increasing vasodilation

and renal function, promoting wound healing and increasing production of angiogenic cytokine, comprises administering

relaxin -

INVENTOR: Conrad K P; Lewis M; Unemori E N; Huang X; Tozzi C A

PATENT ASSIGNEE: (CONN-N) CONNETICS CORP.

(UYPI-N) UNIV PITTSBURGH.

(UYNE-N) UNIV NEW JERSEY MEDICINE & DENTISTRY.

PATENT INFO: WO 2001058468 Al 20010816 73p

APPLICATION INFO: WO 2001-US4370 20010209 PRIORITY INFO: US 2000-181408 20000209 US 2000-200284 20000428

US 2000-242216 20001020

DOCUMENT TYPE: Patent LANGUAGE: English

OTHER SOURCE: 2001-514619 [56]
AN AAD14393 DNA DGENE

AB The invention relates to methods of treating diseases related to **vasodilation** by administering pharmaceutically active

relaxin. Relaxin functions to increase both vasodilation and angiogenesis in males as well as females and is therefore useful in treating a wide variety of diseases relating to vasoconstriction. The method is used for treating renal or pulmonary hypertension, treating ischaemic conditions such as ischaemic wound, stroke or ischaemic cardiac conditional, for increasing production of an angiogenic cytokine such as basic fibroblast growth factor (bFGF) or a vascular endothelial growth factor, increasing vasodilation , increasing renal function by increasing glomerular filtration rate, promoting wound healing, increasing nitric oxide production in an endothelial cell of a blood vessel endothelium and for increasing endothelin type B receptor activation in an endothelial cell in a blood vessel endothelium. Relaxin is useful for treating diseases related to vasoconstriction such as angiotensin-II-mediated vasoconstriction, endothelin-mediated vasoconstriction and for increasing angiogenesis and to promote neovascularisation in both males and females. It also promotes renal vasodilation and hyperfiltration. The gene encoding relaxin is used in gene therapy. The present sequence is a sense RT (reverse transcription) - PCR primer used to amplify rat vascular endothelial cell growth factor (VEGF) 120.

ANSWER 29 OF 32 DGENE (C) 2002 THOMSON DERWENT L9

ACCESSION NUMBER: AAD14392 DNA **DGENE**

Treating pulmonary or renal hypertension and an TITLE:

ischemic condition, increasing vasodilation

and renal function, promoting wound healing and increasing production of angiogenic cytokine, comprises administering

relaxin -

INVENTOR: Conrad K P; Lewis M; Unemori E N; Huang X; Tozzi C A

PATENT ASSIGNEE: (CONN-N) CONNETICS CORP.

UNIV PITTSBURGH. (UYPI-N)

UNIV NEW JERSEY MEDICINE & DENTISTRY. (UYNE-N)

PATENT INFO: WO 2001058468 A1 20010816 73p

APPLICATION INFO: WO 2001-US4370 20010209 US 2000-181408 PRIORITY INFO: 20000209 US 2000-200284 20000428

US 2000-242216 20001020

DOCUMENT TYPE: Patent

LANGUAGE: English

AB

OTHER SOURCE: 2001-514619 [56] AAD14392 DNA DGENE AN

The invention relates to methods of treating diseases related to vasodilation by administering pharmaceutically active relaxin. Relaxin functions to increase both vasodilation and angiogenesis in males as well as females and is therefore useful in treating a wide variety of diseases relating to vasoconstriction. The method is used for treating renal or pulmonary hypertension, treating ischaemic conditions such as ischaemic wound, stroke or ischaemic cardiac conditional, for increasing production of an angiogenic cytokine such as basic fibroblast growth factor (bFGF) or a vascular endothelial growth factor, increasing vasodilation , increasing renal function by increasing glomerular filtration rate, promoting wound healing, increasing nitric oxide production in an endothelial cell of a blood vessel endothelium and for increasing endothelin type B receptor activation in an endothelial cell in a blood vessel endothelium. Relaxin is useful for treating diseases related to vasoconstriction such as angiotensin-II-mediated vasoconstriction, endothelin-mediated vasoconstriction and for increasing angiogenesis and to promote neovascularisation in both males and females. It also promotes renal vasodilation and hyperfiltration. The gene encoding relaxin is used in gene therapy. The present sequence is a sense probe used in the RT (reverse transcription)-PCR analysis of rat vascular endothelial cell growth factor (VEGF) 120.

ANSWER 30 OF 32 DGENE (C) 2002 THOMSON DERWENT ACCESSION NUMBER: AAD14391 DNA DGENE

TITLE: Treating pulmonary or renal hypertension and an

ischemic condition, increasing vasodilation

and renal function, promoting wound healing and increasing production of angiogenic cytokine, comprises administering

relaxin -

INVENTOR: Conrad K P; Lewis M; Unemori E N; Huang X; Tozzi C A

PATENT ASSIGNEE: (CONN-N) CONNETICS CORP.

(UYPI-N) UNIV PITTSBURGH.

(UYNE-N) UNIV NEW JERSEY MEDICINE & DENTISTRY.

PATENT INFO: WO 2001058468 A1 20010816 73p

APPLICATION INFO: WO 2001-US4370 20010209 PRIORITY INFO: US 2000-181408 20000209 US 2000-200284 20000428

US 2000-242216 20001020

DOCUMENT TYPE: Patent LANGUAGE: English

OTHER SOURCE: 2001-514619 [56] AN AAD14391 DNA DGENE

AB The invention relates to methods of treating diseases related to

vasodilation by administering pharmaceutically active

relaxin. Relaxin functions to increase both

vasodilation and angiogenesis in males as well as females and is therefore useful in treating a wide variety of diseases relating to vasoconstriction. The method is used for treating renal or pulmonary hypertension, treating ischaemic conditions such as ischaemic wound, stroke or ischaemic cardiac conditional, for increasing product

wound, stroke or ischaemic cardiac conditional, for increasing production of an angiogenic cytokine such as basic fibroblast growth factor (bFGF) or a vascular endothelial growth factor, increasing vasodilation

, increasing renal function by increasing glomerular filtration rate, promoting wound healing, increasing nitric oxide production in an endothelial cell of a blood vessel endothelium and for increasing endothelin type B receptor activation in an endothelial cell in a blood vessel endothelium. Relaxin is useful for treating diseases

related to vasoconstriction such as angiotensin-II-mediated vasoconstriction, endothelin-mediated vasoconstriction and for increasing angiogenesis and to promote neovascularisation in both males and females. It also promotes renal **vasodilation** and hyperfiltration. The

gene encoding relaxin is used in gene therapy. The present sequence is an alpha sense RT (reverse transcription)-PCR primer used to amplify rat vascular endothelial cell growth factor (VEGF) 164.

L9 ANSWER 31 OF 32 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAD14390 DNA DGENE

TITLE: Treating pulmonary or renal hypertension and an

ischemic condition, increasing vasodilation

and renal function, promoting wound healing and increasing production of angiogenic cytokine, comprises administering

relaxin -

INVENTOR: Conrad K P; Lewis M; Unemori E N; Huang X; Tozzi C A

PATENT ASSIGNEE: (CONN-N) CONNETICS CORP.

(UYPI-N) UNIV PITTSBURGH.

(UYNE-N) UNIV NEW JERSEY MEDICINE & DENTISTRY.

PATENT INFO: WO 2001058468 A1 20010816 73p

APPLICATION INFO: WO 2001-US4370 20010209 PRIORITY INFO: US 2000-181408 20000209 US 2000-200284 20000428

US 2000-200284 20000428 US 2000-242216 20001020

DOCUMENT TYPE: Patent LANGUAGE: English

OTHER SOURCE: 2001-514619 [56]
AN AAD14390 DNA DGENE

AB The invention relates to methods of treating diseases related to

vasodilation by administering pharmaceutically active

relaxin. Relaxin functions to increase both

vasodilation and angiogenesis in males as well as females and is therefore useful in treating a wide variety of diseases relating to

vasoconstriction. The method is used for treating renal or pulmonary hypertension, treating ischaemic conditions such as ischaemic wound, stroke or ischaemic cardiac conditional, for increasing production of an angiogenic cytokine such as basic fibroblast growth factor (bFGF) or a vascular endothelial growth factor, increasing vasodilation , increasing renal function by increasing glomerular filtration rate, promoting wound healing, increasing nitric oxide production in an endothelial cell of a blood vessel endothelium and for increasing endothelin type B receptor activation in an endothelial cell in a blood vessel endothelium. Relaxin is useful for treating diseases related to vasoconstriction such as angiotensin-II-mediated vasoconstriction, endothelin-mediated vasoconstriction and for increasing angiogenesis and to promote neovascularisation in both males and females. It also promotes renal vasodilation and hyperfiltration. The gene encoding relaxin is used in gene therapy. The present sequence is a sense RT (reverse transcription) - PCR primer used to amplify rat vascular endothelial cell growth factor (VEGF) 164.

L9 ANSWER 32 OF 32 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAD14389 DNA DGENE

TITLE: Treating pulmonary or renal hypertension and an

ischemic condition, increasing vasodilation

and renal function, promoting wound healing and increasing production of angiogenic cytokine, comprises administering

relaxin -

INVENTOR: Conrad K P; Lewis M; Unemori E N; Huang X; Tozzi C A

PATENT ASSIGNEE: (CONN-N) CONNETICS CORP.

(UYPI-N) UNIV PITTSBURGH.

(UYNE-N) UNIV NEW JERSEY MEDICINE & DENTISTRY.

PATENT INFO: WO 2001058468 A1 20010816 73p

APPLICATION INFO: WO 2001-US4370 20010209

PRIORITY INFO: US 2000-181408 20000209 US 2000-200284 20000428

US 2000-242216 20001020

DOCUMENT TYPE: Patent LANGUAGE: English

OTHER SOURCE: 2001-514619 [56]

AN AAD14389 DNA DGENE

AB The invention relates to methods of treating disease

The invention relates to methods of treating diseases related to vasodilation by administering pharmaceutically active relaxin. Relaxin functions to increase both vasodilation and angiogenesis in males as well as females and is therefore useful in treating a wide variety of diseases relating to vasoconstriction. The method is used for treating renal or pulmonary hypertension, treating ischaemic conditions such as ischaemic wound, stroke or ischaemic cardiac conditional, for increasing production of an angiogenic cytokine such as basic fibroblast growth factor (bFGF) or a vascular endothelial growth factor, increasing vasodilation , increasing renal function by increasing glomerular filtration rate, promoting wound healing, increasing nitric oxide production in an endothelial cell of a blood vessel endothelium and for increasing endothelin type B receptor activation in an endothelial cell in a blood vessel endothelium. Relaxin is useful for treating diseases related to vasoconstriction such as angiotensin-II-mediated vasoconstriction, endothelin-mediated vasoconstriction and for increasing angiogenesis and to promote neovascularisation in both males and females. It also promotes renal vasodilation and hyperfiltration. The gene encoding relaxin is used in gene therapy. The present sequence is a sense probe used in the RT (reverse transcription)-PCR analysis of rat vascular endothelial cell growth factor (VEGF) 164.